var title_f14_9_14480="Adenomatoid malform CT II";
var content_f14_9_14480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic adenomatoid malformation of the right upper lobe in a 19-year-old patient with pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small cysts are present in the axillary region of the right upper lobe. The gas-liquid interface is evidence for superimposed recent infection of cystic adenomatoid malformation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14480=[""].join("\n");
var outline_f14_9_14480=null;
var title_f14_9_14481="Calculator: Peak Expiratory Flow Prediction";
var content_f14_9_14481=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"PeakExpFlow_form\" name=\"PeakExpFlow_form\" onkeydown=\"clrResults();\" onkeyup=\"PeakExpFlow_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Peak Expiratory Flow Prediction",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         PEFFemale = e",
"         <sup>",
"          ((0.376*ln(Age))-(0.012*Age)-(58.8/Height)+5.63)",
"         </sup>",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         PEFMale = e",
"         <sup>",
"          ((0.544*ln(Age))-(0.0151*Age)-(74.7/Height)+5.48)",
"         </sup>",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Height",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Height_param\" onblur=\"PeakExpFlow_fx(); minMaxCheck();\" onchange=\"PeakExpFlow_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"PeakExpFlow_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|cm\">",
"              cm",
"             </option>",
"             <option value=\"2.54|0|in\">",
"              in",
"             </option>",
"             <option value=\"100|0|m\">",
"              m",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Age",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Age_param\" onblur=\"PeakExpFlow_fx(); minMaxCheck();\" onchange=\"PeakExpFlow_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"PeakExpFlow_fx();\" style=\"width:105px;\">",
"             <option value=\"0.0833333333333333|0|mo\">",
"              mo",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|yr\">",
"              yr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             PEF Female",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"PEF_Female_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"PEF_Female_unit\" onchange=\"PeakExpFlow_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|L/min\">",
"               L/min",
"              </option>",
"              <option value=\"60|0|L/sec\">",
"               L/sec",
"              </option>",
"              <option value=\"1.666666667e-05|0|mL/hr\">",
"               mL/hr",
"              </option>",
"              <option value=\"0.001|0|mL/min\">",
"               mL/min",
"              </option>",
"              <option value=\"0.06|0|mL/sec\">",
"               mL/sec",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             PEF Male",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"PEF_Male_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"PEF_Male_unit\" onchange=\"PeakExpFlow_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|L/min\">",
"               L/min",
"              </option>",
"              <option value=\"60|0|L/sec\">",
"               L/sec",
"              </option>",
"              <option value=\"1.666666667e-05|0|mL/hr\">",
"               mL/hr",
"              </option>",
"              <option value=\"0.001|0|mL/min\">",
"               mL/min",
"              </option>",
"              <option value=\"0.06|0|mL/sec\">",
"               mL/sec",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Nunn AJ, Gregg I. New regression equations for predicting peak expiratory flow in adults.",
"       <i>",
"        BMJ",
"       </i>",
"       . 1989 Apr 22;298(6680):1068-70.",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Radeos MS, Camargo CA. Predicted peak expiratory flow: differences across formulae in the literature.",
"       <i>",
"        Am J Emerg Med",
"       </i>",
"       .  2004 Nov;22(7):516-21.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14481=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function PeakExpFlow_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.PeakExpFlow_form){",
"",
"",
"doCalc = true;",
"if (Height_param.value.indexOf(',') >= 0){ Height_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = 0;",
"PEF_Female =  eTo((0.376 * ln(Age)) - (0.012 * Age) - (58.8 / Height) + 5.63);",
"",
"unit_parts = PEF_Female_unit.options[PEF_Female_unit.selectedIndex].value.split('|');",
"if (doCalc) PEF_Female_param.value = fixDP((PEF_Female - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"PEF_Male =  eTo((0.544 * ln(Age)) - (0.0151 * Age) - (74.7 / Height) + 5.48);",
"",
"unit_parts = PEF_Male_unit.options[PEF_Male_unit.selectedIndex].value.split('|');",
"if (doCalc) PEF_Male_param.value = fixDP((PEF_Male - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PeakExpFlow_form){",
"",
"if (Age_param.value && Age < 15) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 15 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 85) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 85 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.PeakExpFlow_form){",
"",
"PEF_Female_param.value = '';",
"PEF_Male_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f14_9_14481=null;
var title_f14_9_14482="Unilateral facet dislocation CT";
var content_f14_9_14482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Unilateral facet dislocation (C5/C6)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Unilateral facet dislocations involve flexion and rotation. Rotation occurs around one of the facet joints; dislocation occurs at the contralateral facet joint, with the superior facet moving over the inferior facet. In the CT images above note the normal juxtaposition of the facets on the right and the dislocation on the left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14482=[""].join("\n");
var outline_f14_9_14482=null;
var title_f14_9_14483="Patient information: Interstitial lung disease (The Basics)";
var content_f14_9_14483=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/17/3347\">",
"         Patient information: Asbestos exposure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/11/43186\">",
"         Patient information: Breathing tests (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/0/43011\">",
"         Patient information: Cough in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?4/63/5106\">",
"         Patient information: Dermatomyositis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/31/7666\">",
"         Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/42/22178\">",
"         Patient information: Lupus (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/47/30450\">",
"         Patient information: Polymyositis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/14/20705\">",
"         Patient information: Sarcoidosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/46/6883\">",
"         Patient information: Shortness of breath (dyspnea) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/57/37778\">",
"         Patient information: Steroid medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/34/28195\">",
"         Patient information: Chronic cough in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/38/30308\">",
"         Patient information: Pneumonia in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/61/21463\">",
"         Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/35/5683\">",
"         Patient information: Sarcoidosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/50/28450\">",
"         Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/35/29238\">",
"         Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Interstitial lung disease (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H68595665\">",
"      <span class=\"h1\">",
"       What is interstitial lung disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Interstitial lung disease is the medical term for a group of lung disorders that cause similar symptoms and changes in the lungs. Interstitial lung disease causes inflammation and sometimes scarring in the lungs. This makes it hard for oxygen to get from the air into the lungs, which can make it hard to breathe.",
"     </p>",
"     <p>",
"      There are many causes of interstitial lung disease, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Autoimmune diseases &ndash; These are diseases in which the body&rsquo;s infection-fighting system attacks healthy tissue instead of infections.",
"       </li>",
"       <li>",
"        Other medical conditions",
"       </li>",
"       <li>",
"        Certain medicines",
"       </li>",
"       <li>",
"        Harmful substances that are breathed into the lungs over a long period of time &ndash; These include cigarette smoke, mold, chemicals, or dust from asbestos, silica, metals, or coal.",
"       </li>",
"       <li>",
"        Radiation (high doses of X-rays)",
"       </li>",
"       <li>",
"        Certain lung infections",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In some cases, though, doctors don&rsquo;t know what is causing a person&rsquo;s interstitial lung disease.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H68595680\">",
"      <span class=\"h1\">",
"       What are the symptoms of interstitial lung disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Early on, some people have no symptoms. Their doctor or nurse finds out they have interstitial lung disease when they have a chest X-ray or breathing tests done for another reason.",
"     </p>",
"     <p>",
"      When interstitial lung disease causes symptoms, the most common symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing or feeling short of breath, especially with activity or exercise",
"       </li>",
"       <li>",
"        A dry cough that lasts for a long time",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some medical conditions that cause interstitial lung disease also cause symptoms in other parts of the body. For example, some autoimmune disorders also cause skin or joint symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H68595695\">",
"      <span class=\"h1\">",
"       Is there a test for interstitial lung disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have interstitial lung disease, your doctor or nurse will want to know what&rsquo;s causing it. He or she will ask about your medicines, past medical conditions, and whether you have been around harmful substances you might have breathed in.",
"     </p>",
"     <p>",
"      He or she will also order tests. The tests that are usually done to figure out the cause of interstitial lung disease include the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A chest X-ray",
"       </li>",
"       <li>",
"        A CT scan of the chest &ndash; A CT scan is an imaging test that creates pictures of the inside of the body.",
"       </li>",
"       <li>",
"        An electrocardiogram (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;) &ndash; This test measures the electrical activity in the heart. It can show whether people also have a heart problem.",
"       </li>",
"       <li>",
"        Breathing tests, also called &ldquo;pulmonary function tests&rdquo; &ndash; These tests measure how well the lungs are working.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In some cases, people might also have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Bronchoscopy &ndash; This is a procedure in which a doctor uses a thin tube (called a &ldquo;bronchoscope&rdquo;) to look inside the lungs and get a sample of fluid.",
"       </li>",
"       <li>",
"        A lung biopsy &ndash; For a lung biopsy, a doctor does surgery or a procedure to take a small sample of tissue from the lung. Then another doctor looks at the sample under a microscope. Not everyone will need a lung biopsy. It is done only if all of the other tests don&rsquo;t show what&rsquo;s causing the interstitial lung disease.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H68595710\">",
"      <span class=\"h1\">",
"       How is interstitial lung disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the cause of your interstitial lung disease and how severe your symptoms are.",
"     </p>",
"     <p>",
"      If your lung disease is caused by an infection, your doctor will prescribe medicines to kill the germs causing the infection.",
"     </p>",
"     <p>",
"      If your lung disease is caused by a medicine you take, your doctor will recommend that you stop taking that medicine.",
"     </p>",
"     <p>",
"      Many people with interstitial lung disease are treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Extra oxygen (that you carry around with you in a tank)",
"       </li>",
"       <li>",
"        Steroid medicines &ndash; These are different from the steroids athletes take to build muscle. These steroids help reduce inflammation.",
"       </li>",
"       <li>",
"        Other medicines that &ldquo;calm down&rdquo; the immune system",
"       </li>",
"       <li>",
"        Pulmonary rehab &ndash; In pulmonary rehab, people learn exercises and ways to breathe that can help with symptoms.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In some cases, people with severe interstitial lung disease might be treated with a lung transplant. This is surgery to replace 1 or both diseased lungs with healthy lungs.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H68595725\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"       Patient information: Cough in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=see_link\">",
"       Patient information: Breathing tests (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/17/3347?source=see_link\">",
"       Patient information: Asbestos exposure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/31/7666?source=see_link\">",
"       Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=see_link\">",
"       Patient information: Sarcoidosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/63/5106?source=see_link\">",
"       Patient information: Dermatomyositis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/47/30450?source=see_link\">",
"       Patient information: Polymyositis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/42/22178?source=see_link\">",
"       Patient information: Lupus (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=see_link\">",
"       Patient information: Steroid medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=see_link\">",
"       Patient information: Chronic cough in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"       Patient information: Pneumonia in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=see_link\">",
"       Patient information: Sarcoidosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"       Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"       Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/9/14483?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86972 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-99C72D4C66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14483=[""].join("\n");
var outline_f14_9_14483=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68595665\">",
"      What is interstitial lung disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68595680\">",
"      What are the symptoms of interstitial lung disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68595695\">",
"      Is there a test for interstitial lung disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68595710\">",
"      How is interstitial lung disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68595725\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/17/3347?source=related_link\">",
"      Patient information: Asbestos exposure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=related_link\">",
"      Patient information: Breathing tests (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=related_link\">",
"      Patient information: Chronic cough in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=related_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/63/5106?source=related_link\">",
"      Patient information: Dermatomyositis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/31/7666?source=related_link\">",
"      Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/42/22178?source=related_link\">",
"      Patient information: Lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/47/30450?source=related_link\">",
"      Patient information: Polymyositis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/35/5683?source=related_link\">",
"      Patient information: Sarcoidosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=related_link\">",
"      Patient information: Sarcoidosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=related_link\">",
"      Patient information: Steroid medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_9_14484="Rilonacept: Pediatric drug information";
var content_f14_9_14484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rilonacept: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=see_link\">",
"    see \"Rilonacept: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/6/24676?source=see_link\">",
"    see \"Rilonacept: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5726811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Arcalyst&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13371695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Interleukin-1 Receptor Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13371703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=see_link\">",
"      see \"Rilonacept: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ:",
"     <b>",
"      Cryopyrin-associated periodic syndromes (CAPS):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents 12-17 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: Loading dose 4.4 mg/kg; maximum dose: 320 mg/dose;",
"     <b>",
"      Note:",
"     </b>",
"     Loading dose may be divided into 1 or 2 separate injections (maximum injection volume: 2 mL/injection) and given on the same day at different sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance dose: Begin 1 week after loading dose: 2.2 mg/kg/dose once weekly; maximum dose: 160 mg/dose;",
"     <b>",
"      Note:",
"     </b>",
"     Do not administer more frequently than once weekly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents &ge;18 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: Loading dose: 320 mg administered as 2 separate injections (160 mg each) on the same day at different sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: Begin 1 week after loading dose: 160 mg once weekly;",
"     <b>",
"      Note:",
"     </b>",
"     Do not administer more frequently than once weekly.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5931890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arcalyst&reg;: 220 mg [contains sucrose 2%; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5931783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13371704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Reconstitute with 2.3 mL of preservative-free SWI; shake vial for 1 minute then let sit for 1 minute; resulting solution is 80 mg/mL. Administer subcutaneously, if total dose exceeds 2 mL, dose should be divided into 2 injections at different sites; rotate injection sites (thigh, abdomen, upper arm); avoid sites that are bruised, red, tender, or hard.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13371700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vial at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; protect from light. After reconstitution, protect from light and store at room temperature; use within 3 hours of reconstitution. Reconstituted solution is described as viscous, clear, and colorless to pale yellow.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13371696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS) (FDA approved in ages &ge;12 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F5931807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Hypoesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Injection site reactions (majority mild-moderate; typically lasting 1-2 days; characterized by erythema, bruising, dermatitis, inflammation, pain, pruritus, swelling, urticaria, vesicles, warmth, and hemorrhage)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Cough, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Antibody formation to rilonacept, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: HDL cholesterol increased, LDL cholesterol increased, neutropenia (transient), triglycerides increased, total cholesterol increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13371697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rilonacept or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13371708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use may affect defenses against malignancies; impact on the development and course of malignancies is not fully defined. Patients should be brought up-to-date with all immunizations, including pneumococcal and influenza, before initiating therapy; live vaccines should not be given concurrently. No data are available concerning the effects of therapy on vaccine effectiveness or secondary transmission of live vaccines in patients receiving therapy. May increase serum lipids (eg, total cholesterol, HDL, LDL, triglycerides); monitor lipid profile periodically (eg, after 2-3 months of therapy); in some cases, initiation of lipid-lowering therapy may be necessary. Local injection site reactions frequently reported; majority mild-moderate; typically lasting 1-2 days; characterized by erythema, bruising, dermatitis, inflammation, pain, pruritus, swelling, urticaria, vesicles, warmth, and hemorrhage. Antibody-formation to rilonacept has been reported (incidence: 35%); clinical impact is not fully defined; however, no correlation with clinical effectiveness or safety was noted during trials.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13371698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May decrease immune response to infection due to interleukin-1 (IL-1) blockade; serious infections have been reported during rilonacept therapy. Exercise caution when considering use in patients with a history of new or recurrent infections, conditions that predispose them to infections, latent infections [eg, tuberculosis (TB)] or opportunistic infections. Patients who develop a new infection while undergoing treatment should be monitored closely; discontinue therapy if serious infection develops. Risk of serious infection increased with concurrent tumor necrosis factor (TNF)-blocker (eg, etanercept) use; manufacturer recommends avoiding concurrent therapy with TNF blockers and other IL-1 blocking agents (eg, canakinumab, anakinra). Avoid use in patients with active TB; patients should be evaluated for latent tuberculosis infection with a tuberculin skin test prior to starting therapy. Latent TB infections should be treated prior to initiating rilonacept therapy; monitor for signs/symptoms of active TB during therapy. May cause hypersensitivity reactions (rare); discontinue use if occurs.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5931812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-TNF Agents: May enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Interleukin-1 Inhibitors may enhance the adverse/toxic effect of Canakinumab. Whether such a combination will also alter the therapeutic response to one or both agents is unclear.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5931787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5931788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenic effects and fetal loss. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit to the mother outweighs potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13371705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, C-reactive protein (CRP), serum amyloid A; signs or symptoms of infection; latent TB screening (prior to initiating therapy), lipid profile (2-3 months after initiating therapy and periodically thereafter)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13371701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rilonacept reduces inflammation by binding to IL-1&beta; (some binding of IL-1&alpha; and IL-1 receptor antagonist) and preventing interaction with cell surface receptors. Cryopyrin-associated periodic syndromes (CAPS) refers to rare genetic syndromes caused by mutations in the nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3 (NLRP-3) gene or the cold-induced autoinflammatory syndrome-1 (CIAS1) gene. Cryopyrin, a protein encoded by this gene, regulates interleukin-1 beta (IL-1&beta;) activation. Deficiency of cryopyrin results in excessive inflammation.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F13371709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Steady-state concentrations reached in ~6 weeks",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13371706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/6/24676?source=see_link\">",
"      see \"Rilonacept: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform prescriber of history of tuberculosis. Patient may be more susceptible to infection. May cause headache, diarrhea, nausea, and irritation of the throat or nose. Report persistent fever; signs of infection; flu-like symptoms; persistent nausea, diarrhea, or abdominal pain; skin rash; or pain at injection site. Redness, pain, itching, or swelling at the site of injection may occur. This typically lasts 1-2 days. Do not receive any immunizations unless approved by prescriber.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17061 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-109.230.63.219-37932DBF7B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14484=[""].join("\n");
var outline_f14_9_14484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5726811\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371695\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371703\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931890\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931783\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371704\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371700\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371696\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931807\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371697\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371708\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371698\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299999\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931812\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931787\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5931788\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371705\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371701\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371709\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13371706\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17061\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17061|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=related_link\">",
"      Rilonacept: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/6/24676?source=related_link\">",
"      Rilonacept: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_9_14485="Cap polyposis";
var content_f14_9_14485=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cap polyposis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14485/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14485/contributors\">",
"     Amy Lo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14485/contributors\">",
"     Young-Mee Lee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14485/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14485/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14485/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14485/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/9/14485/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cap polyposis is a rare condition characterized by mucoid, bloody diarrhea associated with erythematous, inflammatory colonic polyps covered by a cap of fibrinopurulent mucous. The disorder was first described in 1985 and has subsequently been reported in occasional case series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Despite its rarity, recognition is important since its clinical symptoms may be similar to inflammatory bowel disease or irritable bowel syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of cap polyposis has not been well studied. It occurs predominantly in women, most frequently during the fifth decade of life. However, it has been described in men and women ranging from 12 to 76 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology is not well understood. It was initially considered a form of inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/1\">",
"     1",
"    </a>",
"    ]. Others suggested an infectious origin such as Helicobacter pylori or Escherichia coli 018 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], based in part upon symptomatic and colonoscopic improvement after treatment with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. Cap polyposis has also been described following pelvic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible association with mucosal prolapse syndrome (MPS) has been suggested based upon similar histologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In MPS, mucosal prolapse occurs adjacent to tumors, diverticula, and prolapsed colostomies. Similarly, abnormal colonic motility may result in mucosal prolapse at redundant transverse folds resulting in local ischemia, recurrent mucosal trauma, and the development of cap polyposis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/10\">",
"     10",
"    </a>",
"    ]. Symptomatically, the abnormal colonic motility results in constipation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythematous, pedunculated, or sessile polyps are found typically in the rectosigmoid colon, but may involve the entire colon [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The polyps are usually located at the apices of enlarged transverse mucosal folds and can number from a few to many [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/1\">",
"     1",
"    </a>",
"    ]. They are often mistaken for inflammatory pseudopolyps. The lesions have a reddish surface with adherent mucous and occasional white specks in the colonic mucosa surrounding them [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. There can be associated central pitting and the typical white mucoid cap. The intervening mucosa is normal. A mild form of the disease has been described characterized by multiple patches of flushed, edematous mucosa separated by normal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/3\">",
"     3",
"    </a>",
"    ]. Whether these patients progress to the more classic form is unclear.",
"   </p>",
"   <p>",
"    The overlying mucus is chemically different from that overlying the normal colon mucosa. There is a predominance of non-sulfated mucins, which have been more characteristically associated with \"transitional mucosa\" seen with colorectal carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/14\">",
"     14",
"    </a>",
"    ], familial polyposis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/15\">",
"     15",
"    </a>",
"    ], colorectal adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/16\">",
"     16",
"    </a>",
"    ], and ulcerative colitis with dysplastic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The abnormal mucins do not appear to have a direct pathologic effect but rather appear to reflect abnormally differentiated epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/19\">",
"     19",
"    </a>",
"    ]. Cap polyposis is not known to be a premalignant condition.",
"   </p>",
"   <p>",
"    On microscopic evaluation, elongated, hyperplastic-appearing glands are found with a mixed inflammatory infiltrate in the lamina propria and fibromuscular obliteration of the lamina propria (",
"    <a class=\"graphic graphic_picture graphicRef70137 \" href=\"UTD.htm?23/58/24482\">",
"     picture 1",
"    </a>",
"    ). The cap overlying the polyps is formed by mucus, fibrin, and leukocytes. Some of these features have corresponding findings on magnification endoscopy and endoscopic ultrasound. Magnifying colonoscopy shows a mixture of round crypts in the depressed center with long branching crypts in the surrounding elevated areas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/20\">",
"     20",
"    </a>",
"    ]. Endoscopic ultrasound shows hypoechoic thickening of the second sonographic layer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most reports describe women with weeks to months of mucoid and bloody diarrhea. Patients may also have abdominal pain, tenesmus, weight loss, constipation, and hypoproteinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/10\">",
"     10",
"    </a>",
"    ]. The most common clinical features in a literature review were rectal bleeding (82 percent), chronic straining during defecation and constipation (64 percent), and mucous diarrhea (46 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/22\">",
"     22",
"    </a>",
"    ]. Some patients were previously diagnosed with ulcerative colitis and treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , steroids and antibiotics, often without effect.",
"   </p>",
"   <p>",
"    Laboratory studies are nonspecific. As noted above, patients with severe disease can have hypoproteinemia. Other laboratory studies, including acute phase reactants, are typically unremarkable [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the natural history of cap polyposis are limited to case reports and retrospective series involving fewer than 20 patients with follow-up limited to 72 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/22\">",
"     22",
"    </a>",
"    ]. Most have chronic recurrent symptoms requiring multiple treatment modalities, although spontaneous resolution has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cap polyposis may begin as a solitary pedunculated lesion. Other lesions may extend distally or proximally [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/23\">",
"     23",
"    </a>",
"    ]. The lesions may also evolve along the anastomotic line after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. There have been no reports of malignant transformation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis requires a high index of suspicion since, as noted above, the lesions may resemble inflammatory polyps (",
"    <a class=\"graphic graphic_picture graphicRef55852 \" href=\"UTD.htm?31/13/31955\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef66543 graphicRef75263 graphicRef57358 \" href=\"UTD.htm?42/56/43913\">",
"     picture 3A-C",
"    </a>",
"    ). The diagnosis is established during colonoscopy by recognizing the typical colonoscopic findings of erythematous polyps with an adherent mucoid cap (",
"    <a class=\"external\" href=\"file://dave1.mgh.harvard.edu/ViewFilms.cfm?Film_id=291\">",
"     file://dave1.mgh.harvard.edu/ViewFilms.cfm?Film_id=291",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Representative biopsies should be obtained, which can confirm the diagnosis. One authority suggests that the diagnosis be made only in patients with a constellation of symptoms and findings, not just the observation of a single polyp with a cap of granulation tissue or a collection of such polyps at an anastomosis in an asymptomatic patient [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes inflammatory polyps, colon cancer, familial adenomatous polyposis, MUTYH polyposis, familial juvenile polyposis, inflammatory bowel disease, diverticular colitis, and solitary rectal ulcer syndrome. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal treatment has not been established. As a general rule, treatment should be directed at improving clinical features of the disease. Initial treatment should include avoidance of constipation and straining, as there is a suggested relationship of cap polyposis with abnormal colonic motility. Several other approaches have been described in case reports and small series including anti-inflammatory agents, antibiotics, immunomodulators, and endoscopic and surgical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral aminosalicylates and systemic and topical steroids were ineffective in a series of three patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/3\">",
"       3",
"      </a>",
"      ]. However, in a series that included five patients treated with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      , steroid treatment lead to remission in three, all of whom recurred following withdrawal of steroid therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/25\">",
"       25",
"      </a>",
"      ]. A second course of steroid therapy again induced remission, though one of the patients had another recurrence once the steroids were stopped.",
"     </li>",
"     <li>",
"      A case report described resolution with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (250 mg orally three times daily for at least two weeks) after treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      and broad-spectrum antibiotics had failed [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/5\">",
"       5",
"      </a>",
"      ]. Repeat endoscopy at two weeks showed continued polyposis, but microscopic examination of biopsy specimens showed a significant decrease in the inflammatory infiltrate. In other studies, no benefit from metronidazole was found [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/3,25-27\">",
"       3,25-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One patient achieved complete clinical, endoscopic, and histologic remission after four infusions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      over 32 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/10\">",
"       10",
"      </a>",
"      ]. A separate case report describes another patient with clinical and endoscopic improvement four weeks after a single infusion of infliximab; routine follow-up colonoscopy three years later documented endoscopic resolution [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/26\">",
"       26",
"      </a>",
"      ]. However, in another report, a patient showed no benefit after a similar treatment regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three reports described remission in a total of seven patients with intractable symptoms following eradication therapy of Helicobacter pylori infection [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/3,6,29\">",
"       3,6,29",
"      </a>",
"      ]. The two-week treatment consisted of a proton pump inhibitor and two antibiotics (typically",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      ). However, in another report, one patient who was successfully treated for H. pylori showed no improvement, whereas a second patient in whom eradication therapy failed had a partial improvement [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment regimens for Helicobacter pylori\", section on 'Triple therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Polyp removal by argon plasma coagulation or endoscopic polypectomy appears to provide only temporary relief [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/3\">",
"       3",
"      </a>",
"      ], except possibly in patients who have only solitary lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/22\">",
"       22",
"      </a>",
"      ]. Anecdotal experience suggests a possible increased risk of postpolypectomy bleeding.",
"     </li>",
"     <li>",
"      Proctocolectomy has been used for intractable symptoms. Full colonoscopic evaluation just prior to surgery is advised to determine the extent of disease. One study reported that four patients undergoing anterior resection were symptom-free at a median of 48 months [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/22\">",
"       22",
"      </a>",
"      ]. However, symptomatic polyposis can recur [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/7,27\">",
"       7,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Spontaneous remission has also been reported. In a report of seven patients, spontaneous remission occurred in three 18, 54, and 72 months after diagnosis, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14485/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cap polyposis is a rare condition characterized by mucoid, bloody diarrhea associated with erythematous, inflammatory colonic polyps covered by a cap of fibrinopurulent mucous.",
"     </li>",
"     <li>",
"      The most common clinical features include rectal bleeding, chronic straining at stool and constipation, and mucous diarrhea.",
"     </li>",
"     <li>",
"      The diagnosis is established during colonoscopy by recognizing the typical colonoscopic findings of erythematous polyps with an adherent mucoid cap in a symptomatic patient. Representative biopsies should be obtained, which can confirm the diagnosis.",
"     </li>",
"     <li>",
"      The differential diagnosis includes inflammatory polyps, colon cancer, familial adenomatous polyposis, MUTYH polyposis, familial juvenile polyposis, inflammatory bowel disease, diverticular colitis, and solitary rectal ulcer syndrome.",
"     </li>",
"     <li>",
"      Optimal treatment has not been established and thus recommendations are based mainly on clinical experience (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Thus, the suggestions below should be considered on an individual-patient basis.",
"      <br/>",
"      <br/>",
"      We suggest that asymptomatic patients be followed periodically without specific treatment. In those who are symptomatic, we suggest initial treatment aimed at relieving straining and constipation since it may contribute to the development of the disorder. We suggest endoscopic polypectomy for patients with a solitary lesion or only a few lesions. For patients who continue to be symptomatic we suggest testing and treating H. pylori infection. We suggest surgery for patients with refractory symptoms despite the above measures.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/1\">",
"      Williams GT, Bussey HJ, Morson BC. Inflammatory \"cap\" polyps of the large intestine. Br J Surg 1985; 72:S133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/2\">",
"      Tomiyama R, Kinjo F, Kinjo N, et al. Gastrointestinal: cap polyposis. J Gastroenterol Hepatol 2003; 18:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/3\">",
"      Akamatsu T, Nakamura N, Kawamura Y, et al. Possible relationship between Helicobacter pylori infection and cap polyposis of the colon. Helicobacter 2004; 9:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/4\">",
"      G&eacute;h&eacute;not M, Colombel JF, Wolschies E, et al. Cap polyposis occurring in the postoperative course of pelvic surgery. Gut 1994; 35:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/5\">",
"      Shimizu K, Koga H, Iida M, et al. Does metronidazole cure cap polyposis by its antiinflammatory actions instead of by its antibiotic action? A case study. Dig Dis Sci 2002; 47:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/6\">",
"      Nakagawa Y, Nagai T, Okawara H, et al. Cap polyposis (CP) which relapsed after remission by avoiding straining at defecation, and was cured by Helicobacter pylori eradication therapy. Intern Med 2009; 48:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/7\">",
"      Konishi T, Watanabe T, Takei Y, et al. Confined progression of cap polyposis along the anastomotic line, implicating the role of inflammatory responses in the pathogenesis. Gastrointest Endosc 2005; 62:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/8\">",
"      Konishi T, Watanabe T, Takei Y, et al. Cap polyposis: an inflammatory disorder or a spectrum of mucosal prolapse syndrome? Gut 2005; 54:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/9\">",
"      Oriuchi T, Kinouchi Y, Kimura M, et al. Successful treatment of cap polyposis by avoidance of intraluminal trauma: clues to pathogenesis. Am J Gastroenterol 2000; 95:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/10\">",
"      Bookman ID, Redston MS, Greenberg GR. Successful treatment of cap polyposis with infliximab. Gastroenterology 2004; 126:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/11\">",
"      Sadamoto Y, Jimi S, Harada N, et al. Asymptomatic cap polyposis from the sigmoid colon to the cecum. Gastrointest Endosc 2001; 54:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/12\">",
"      Isomoto H, Urata M, Nakagoe T, et al. Proximal extension of cap polyposis confirmed by colonoscopy. Gastrointest Endosc 2001; 54:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/13\">",
"      Esaki M, Matsumoto T, Kobayashi H, et al. Cap polyposis of the colon and rectum: an analysis of endoscopic findings. Endoscopy 2001; 33:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/14\">",
"      Isaacson P, Attwood PR. Failure to demonstrate specificity of the morphological and histochemical changes in mucosa adjacent to colonic carcinoma (transitional mucosa). J Clin Pathol 1979; 32:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/15\">",
"      Filipe MI, Mughal S, Bussey HJ. Patterns of mucus secretion in the colonic epithelium in familial polyposis. Invest Cell Path 1980; 3:320.",
"     </a>",
"    </li>",
"    <li>",
"     Filipe MI. Mucins of normal, premalignant and malignant colonic mucosa. In: Progress in cancer research and therapy, Wolman SR, Matromarino AJ (Eds), New York 1984. p.237.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/17\">",
"      Habib NA, Dawson PM, Krausz T, et al. A study of histochemical changes in mucus from patients with ulcerative colitis, Crohn's disease, and diverticular disease of the colon. Dis Colon Rectum 1986; 29:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/18\">",
"      Ehsanullah M, Filipe MI, Gazzard B. Mucin secretion in inflammatory bowel disease: correlation with disease activity and dysplasia. Gut 1982; 23:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/19\">",
"      Buisine MP, Colombel JF, Lecomte-Houcke M, et al. Abnormal mucus in cap polyposis. Gut 1998; 42:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/20\">",
"      Kajihara H, Uno Y, Ying H, et al. Features of cap polyposis by magnifying colonoscopy. Gastrointest Endosc 2000; 52:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/21\">",
"      Ohkawara T, Kato M, Nakagawa S, et al. Spontaneous resolution of cap polyposis: case report. Gastrointest Endosc 2003; 57:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/22\">",
"      Ng KH, Mathur P, Kumarasinghe MP, et al. Cap polyposis: further experience and review. Dis Colon Rectum 2004; 47:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/23\">",
"      Chinen T, Misawa T, Yao T, et al. Pedunculated cap polyps preceding the development of cap polyposis: case report. Gastrointest Endosc 2005; 61:338.",
"     </a>",
"    </li>",
"    <li>",
"     Jerome D, 2005, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/25\">",
"      Chang HS, Yang SK, Kim MJ, et al. Long-term outcome of cap polyposis, with special reference to the effects of steroid therapy. Gastrointest Endosc 2012; 75:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/26\">",
"      Kim ES, Jeen YT, Keum B, et al. Remission of cap polyposis maintained for more than three years after infliximab treatment. Gut Liver 2009; 3:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/27\">",
"      Gallegos M, Lau C, Bradly DP, et al. Cap polyposis with protein-losing enteropathy. Gastroenterol Hepatol (N Y) 2011; 7:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/28\">",
"      Maunoury V, Breisse M, Desreumaux P, et al. Infliximab failure in cap polyposis. Gut 2005; 54:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14485/abstract/29\">",
"      Oiya H, Okawa K, Aoki T, et al. Cap polyposis cured by Helicobacter pylori eradication therapy. J Gastroenterol 2002; 37:463.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2620 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14485=[""].join("\n");
var outline_f14_9_14485=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2620\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2620|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/58/24482\" title=\"picture 1\">",
"      Cap polyposis Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/13/31955\" title=\"picture 2\">",
"      Cap polyposis Endosc I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/45/16082\" title=\"picture 3A\">",
"      Cap polyposis Endosc II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/17/15634\" title=\"picture 3B\">",
"      Cap polyposis Endosc III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/45/41682\" title=\"picture 3C\">",
"      Cap polyposis Endosc IV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_9_14486="Clinical manifestations and evaluation of chronic critical limb ischemia";
var content_f14_9_14486=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and evaluation of chronic critical limb ischemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14486/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14486/contributors\">",
"     David G Neschis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14486/contributors\">",
"     Michael A Golden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14486/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14486/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14486/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14486/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14486/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/9/14486/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limb-threatening ischemia occurs when arterial blood flow is insufficient to meet the metabolic demands of resting muscle or tissue; it is the most common indication for lower extremity arterial reconstruction. It has been estimated that limb-threatening ischemia occurs in 1 to 2 percent of patients with peripheral artery disease (PAD) who are 50 years of age or older [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the 2007 Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II), acute limb ischemia is defined as a sudden decrease in limb perfusion that causes a potential threat to limb viability (manifested by ischemic rest pain, ischemic ulcers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gangrene) in patients who present within two weeks of the acute event [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with similar manifestations who present later than two weeks are considered to have critical limb ischemia, which is by definition chronic.",
"   </p>",
"   <p>",
"    The natural history of critical limb ischemia usually involves inexorable progression to amputation unless there is an intervention that results in the improvement of arterial perfusion. This is in contrast to the often benign natural history of mild and moderate claudication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations and evaluation of critical limb ischemia. The approaches to therapy of this disorder and a review of acute limb ischemic due acute arterial occlusion of the lower extremities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major manifestations of limb-threatening ischemia are rest pain, ischemic ulcers, and gangrene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Critical limb ischemia is most often seen when two or more levels of the distal arterial tree have either significant stenoses or occlusions. This most often involves aortoiliac and femoropopliteal segments or femoropopliteal and tibial segments [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/1\">",
"     1",
"    </a>",
"    ]. Multiple levels of disease promote severe ischemia by reducing the effectiveness of collateral flow and by lowering distal systolic driving pressures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic rest pain or diffuse pedal ischemia can be described as a severe pain which is not readily controlled by analgesics and which is typically localized in the forefoot and toes of the chronically ischemic extremity. The pain may also be felt more proximally; when this occurs, the pain usually does not spare the distal sites.",
"   </p>",
"   <p>",
"    Ischemic rest pain is brought on or made worse by elevation of the lower extremity and is ameliorated or relieved by limb dependency. Thus, rest pain is often experienced at night or while reclining [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/3\">",
"     3",
"    </a>",
"    ]. Diffuse pedal ischemia is commonly associated with systolic arterial ankle pressures below 40 mmHg and toe pressures below 30 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ischemic ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic ulcers often begin as minor traumatic wounds and then fail to heal because the blood supply is insufficient to meet the increased demands of the healing tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/5\">",
"     5",
"    </a>",
"    ]. The ulcers are often painful and are associated with other manifestations of chronic ischemia including rest pain, pallor, hair loss, and nail hypertrophy.",
"   </p>",
"   <p>",
"    Ischemic ulcers need to be distinguished from venous insufficiency and peripheral neuropathy, which are the other major causes of foot and leg ulcers (",
"    <a class=\"graphic graphic_table graphicRef63577 \" href=\"UTD.htm?5/32/5645\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic ulcers typically form at sites of increased focal pressure such as the lateral malleolus, tips of toes, metatarsal heads, and bunion area. They are usually dry and punctate.",
"     </li>",
"     <li>",
"      Venous ulcers are more commonly located above the medial ankle and are frequently moist, superficial, and diffuse. They are often associated with hemosiderin pigmentation and other evidence of venous insufficiency such as varicosities and worsening symptoms with dependency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients may have combined arterial and venous disease and manifest signs of both arterial and venous insufficiency, while diabetic patients may have both arterial disease, which can involve both the microcirculation and large vessels, and peripheral neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=see_link\">",
"     \"Evaluation of the diabetic foot\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ischemic ulcers, which most often involve the foot, can become infected and may lead to osteomyelitis. The clinical manifestations, diagnosis, and management of such infections is similar to that seen in diabetic foot infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2007 TASC II consensus document on the management of PAD which recommends that all diabetic patients with an ulceration be evaluated for PAD using objective testing [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gangrene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gangrene is characterized by cyanotic, anesthetic tissue associated with or progressing to necrosis; it occurs when arterial blood supply falls below that necessary to meet minimal metabolic requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/5\">",
"     5",
"    </a>",
"    ]. Gangrene can be described as either dry or wet.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dry gangrene is characterized by its hard, dry texture, usually occurring in the distal aspects of toes and fingers, often with a clear demarcation between viable and necrotic tissue. This form of gangrene is more common in patients with atherosclerotic disease and frequently results from embolization to the toe or forefoot. The patient may often give a history of associated claudication or foot and toe pain.",
"      <br/>",
"      <br/>",
"      Once demarcation has occurred, the involved digit may be allowed to autoamputate without further proximal progression of gangrene. However, this is often a process which is both lengthy and disturbing to the patient. On the other hand, many patients with dry gangrene do not have adequate circulation to heal a distal amputation. As a result, most patients should be evaluated with angiography for possible distal bypass in order to improve chances of healing a distal amputation and obtaining limb salvage.",
"     </li>",
"     <li>",
"      Wet gangrene is characterized by its moist appearance, gross swelling, and frequent blistering. It is a true emergency, often occurring in diabetics with decreased sensation who sustain an unrecognized trauma to the toe or foot. If sufficient viable tissue is present to maintain a functional foot, emergent debridement of all affected tissue often results in healing. If the wet gangrene involves an extensive portion of the foot, emergent guillotine amputation may be warranted, with revision to below knee or above knee amputation 72 hours later [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute limb ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute ischemic episode can be induced by distal embolization of proximal atheromatous material to the toes, resulting in the blue toe syndrome, by a large embolus, or to sudden occlusion of a previously stenotic area causing diffuse acute limb ischemia. This topic is discussed in detail separately, but the clinical features will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Blue toe syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blue toe syndrome is characterized by the sudden appearance of a cool, painful, cyanotic toe or forefoot in the often perplexing presence of strong pedal pulses and a warm foot (",
"    <a class=\"graphic graphic_picture graphicRef58761 \" href=\"UTD.htm?2/15/2289\">",
"     picture 1",
"    </a>",
"    ). There may also be scattered areas of petechiae or cyanosis of the soles of the feet.",
"   </p>",
"   <p>",
"    The blue toe syndrome is usually due to embolic occlusion of digital arteries with atherothrombotic material from proximal arterial sources. These episodes portend similar and more severe episodes in the future. Thus, identification and eradication of the embolic source is usually indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/7\">",
"     7",
"    </a>",
"    ]. Expeditious evaluation by angiography is required to evaluate the source; complete exclusion and bypass of the diseased segment are indicated. However, caution is advised for performing angiography in patients who have other signs suggestive of multiple atheroemboli, such as livedo reticularis, since angiography may lead to further embolization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Diffuse acute limb ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse acute limb ischemia is characterized by the sudden onset of pain progressing to numbness and finally paralysis of the extremity, accompanied by pallor, paresthesias, coolness, and absence of palpable pulses. This problem is usually caused by embolic or thrombotic occlusions of native arteries or reconstructions of previous vascular occlusions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular evaluation of a patient with critical limb ischemia begins with a detailed history and careful physical examination. Almost all such patients have evidence of an underlying medical disease including heart disease, diabetes, kidney disease, hypertension, chronic pulmonary disease, or extracranial cerebral vascular disease. Maximal therapy of these conditions must be provided before, during, and after surgery to ensure the best possible outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical examination should include a careful search for bruits, aneurysms, and malignancy. The extremities should be carefully evaluated for the presence and strength of pulses, tissue changes, and evidence of prior vascular intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Noninvasive testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical findings are neither specific nor sensitive enough to design operative therapy. As a result, all patients with evidence of peripheral ischemia should undergo objective testing. This includes both noninvasive tests and either contrast or magnetic resonance angiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Ankle-brachial index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ankle-brachial index (or ankle-arm index) is a simple test, which can be performed at the bedside. The ABI is the ratio of the ankle systolic blood pressure divided by the brachial systolic pressure detected with a Doppler probe. The normal value is 0.9 to 1.2. In general, patients with claudication have an ABI between 0.4 and 0.90, while those with rest pain or tissue loss have an ABI in the range of 0.2 to 0.5 and 0 to 0.4, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Segmental Doppler pressures and volume plethysmography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the presence of arterial occlusive disease has been verified using ABI measurements at rest or during exercise, the level and severity of peripheral vascular disease is routinely assessed by segmental limb pressures or volume plethysmography. Segmental Doppler measurements involve placement of cuffs at the levels of the proximal and distal thigh, calf, and ankle. A 20 mmHg or greater reduction in pressure is considered significant if such a gradient is present either between segments along the same leg or when compared to the same level of the opposite leg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544690#H58544690\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Segmental pressures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several blood pressure cuff positions have been employed to detect the level of peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/8\">",
"     8",
"    </a>",
"    ]. As examples, a significant reduction in pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the thigh, reflects aortoiliac or superficial femoral artery disease",
"     </li>",
"     <li>",
"      At the calf, reflects distal superficial femoral artery or popliteal disease",
"     </li>",
"     <li>",
"      At the ankle, reflects infrapopliteal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a toe pressure of less than 60 percent of the ankle pressure indicates digital artery occlusive disease.",
"   </p>",
"   <p>",
"    Plethysmography, or the measurement of volume change in an organ or limb, is usually used in conjunction with segmental limb pressures to assess the level of arterial disease. This technique is performed by injecting a standard volume of air into pneumatic cuffs placed at various levels along the extremity. Volume changes in the limb segment below the cuff are translated into pulsatile pressure, which is detected by a transducer and then displayed as a pressure pulse contour (",
"    <a class=\"graphic graphic_figure graphicRef73590 \" href=\"UTD.htm?17/49/18205\">",
"     figure 1",
"    </a>",
"    ). This technique is especially helpful in diabetic patients with relatively incompressible proximal vessels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544704#H58544704\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Pulse volume recordings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Duplex imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplex imaging can, in experienced hands, provide accurate localization and quantification of lesions; it can also help differentiate stenoses from occlusions, an advantage over segmental Doppler pressures or plethysmography. However, a great deal of time and expertise are required to perform a complete screening examination of the lower extremity vessels with duplex imaging; as a result, this modality is not the first choice for screening in many vascular laboratories. Nevertheless, the ability of duplex imaging to answer precise questions about specific arterial segments and to measure flow velocities in bypass grafts makes it a useful tool in following known lesions for evidence of progression and for monitoring vascular reconstructions for the development of stenoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544718#H58544718\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     CT Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of multidetector computed tomographic (MDCT) scanners now allows rapid acquisition of high resolution, intravenous contrast enhanced images from patients with suspected peripheral artery disease and is increasingly being used in the evaluation of critical limb ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544732#H58544732\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Other imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Magnetic resonance angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance angiography (MRA) is becoming increasingly popular for the evaluation of lower extremity ischemia, particularly in patients who have a contraindication to standard contrast angiography. Its use as a replacement for conventional contrast angiography requires careful evaluation and significant experience with MRA, and cooperation between the radiologist and vascular surgeon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Peripheral artery disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Contrast angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast angiography remains the gold standard in the evaluation of lower extremity critical limb ischemia. It should be performed in patients without a contraindication who are expected to undergo revascularization. A complete study of the aorta, iliac, femoral, popliteal, and run-off vessels is usually done on both the affected and contralateral sides since atherosclerotic disease is usually bilateral and occurs at multiple levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/13/210?source=see_link\">",
"       \"Patient information: Gangrene (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the following recommendations from the 2007 TASC II consensus document on the management of PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14486/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While critical limb ischemia is a clinical diagnosis, all patients should undergo objective testing",
"     </li>",
"     <li>",
"      All patients with ischemic rest pain or pedal ulcer should be evaluated for critical limb ischemia",
"     </li>",
"     <li>",
"      Patients with critical limb ischemia should be referred to a vascular specialist early in the course of their disease",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14486/abstract/1\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14486/abstract/2\">",
"      Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14486/abstract/3\">",
"      Cranley JJ. Ischemic rest pain. Arch Surg 1969; 98:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14486/abstract/4\">",
"      Suggested standards for reports dealing with lower extremity ischemia. Prepared by the Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1986; 4:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14486/abstract/5\">",
"      DeWeese JA, Leather R, Porter J. Practice guidelines: lower extremity revascularization. J Vasc Surg 1993; 18:280.",
"     </a>",
"    </li>",
"    <li>",
"     Fisher, DFJ. Toe and foot amputation. In: Current Therapy in Vascular Surgery, Ernst, CB, Stanley, JC (Eds), Mosby-Year Book, St. Louis 1995. p.672.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14486/abstract/7\">",
"      Karmody AM, Powers SR, Monaco VJ, Leather RP. \"Blue toe\" syndrome. An indication for limb salvage surgery. Arch Surg 1976; 111:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14486/abstract/8\">",
"      Heintz SE, Bone GE, Slaymaker EE, et al. Value of arterial pressure measurements in the proximal and distal part of the thigh in arterial occlusive disease. Surg Gynecol Obstet 1978; 146:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14486/abstract/9\">",
"      Schernthaner R, Fleischmann D, Stadler A, et al. Value of MDCT angiography in developing treatment strategies for critical limb ischemia. AJR Am J Roentgenol 2009; 192:1416.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8214 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-4E1BBEB838-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14486=[""].join("\n");
var outline_f14_9_14486=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ischemic ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gangrene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Blue toe syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Diffuse acute limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Noninvasive testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Ankle-brachial index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Segmental Doppler pressures and volume plethysmography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Duplex imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - CT Angiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Magnetic resonance angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Contrast angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8214\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8214|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/49/18205\" title=\"figure 1\">",
"      Segmental volume plethysmography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8214|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/15/2289\" title=\"picture 1\">",
"      Blue toe syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8214|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/32/5645\" title=\"table 1\">",
"      Differentiation of foot ulcers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=related_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/13/210?source=related_link\">",
"      Patient information: Gangrene (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_9_14487="Larynx anatomy VL photograph";
var content_f14_9_14487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Larynx appearance with videolaryngoscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several photographs of the larynx obtained with a videolaryngoscope: A) Preintubation view of an adult airway; B) Preintubation view of a pediatric airway; C) Endotracheal tube passing between the vocal cords; D) View of the larynx and hypopharynx (note the horizontally oriented space below the laryngeal inlet, which is the esophagus).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nagdev A. Airway, breathing, circulation: Normal airway. In: Greenberg's Text-Atlas of Emergency Medicine, Greenberg MI, Hendrickson RG, Silverberg M, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14487=[""].join("\n");
var outline_f14_9_14487=null;
var title_f14_9_14488="Normal versus anomalous pancreaticobiliary junction";
var content_f14_9_14488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51092%7EPEDS%2F62147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51092%7EPEDS%2F62147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Normal versus anomalous pancreaticobiliary junction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Types of anomalous pancreaticobiliary junction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     B-P: bileopancreatic type; P-B: pancreaticobiliary type.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14488=[""].join("\n");
var outline_f14_9_14488=null;
var title_f14_9_14489="Occupational asthma: Management, prognosis, and prevention";
var content_f14_9_14489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Occupational asthma: Management, prognosis, and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14489/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14489/contributors\">",
"     Moira Chan-Yeung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14489/contributors\">",
"     Jean-Luc Malo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14489/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14489/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14489/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/9/14489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H603599688\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational asthma (OA) is a form of work-related asthma that is characterized by variable airflow obstruction, airway hyperresponsiveness, and airway inflammation induced by exposures in the work environment rather than exposures encountered outside the workplace [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/1\">",
"     1",
"    </a>",
"    ]. Work-exacerbated asthma (also known as work-aggravated asthma) is defined as preexisting or concurrent asthma that subjectively worsens in the workplace.",
"   </p>",
"   <p>",
"    The agents that cause OA include both immunologic and nonimmunologic stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/2\">",
"     2",
"    </a>",
"    ]. Immunologic OA is the classic form of OA in which the worker&rsquo;s immune system is sensitized to an occupational agent through IgE-mediated or other immune recognition. Nonimmunologic OA is a form of irritant-induced asthma that results from single or multiple exposures to a nonimmunologic, irritant substance at a high level of intensity. Reactive airways dysfunction syndrome (RADS), a form of irritant-induced asthma, is triggered by an acute high level exposure to a nonimmunologic stimulus.",
"   </p>",
"   <p>",
"    The diagnosis of OA is based on the appearance of new-onset asthma since the time of initial occupational exposure to a causative agent, evidence of reversible airflow obstruction (based on pulmonary function testing), and demonstration of sensitization to a potential causative agent.",
"   </p>",
"   <p>",
"    The management, prognosis, and prevention of OA will be reviewed here. The definition, epidemiology, causes, risk factors, pathogenesis, clinical features, evaluation, and diagnosis of OA, and the diagnosis and management of RADS and irritant&ndash;induced asthma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38903?source=see_link\">",
"     \"Occupational asthma: Pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=see_link\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293008290\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of OA requires a combination of avoidance of further exposure to sensitizing agents, reduction in exposure to irritant agents (eg, environmental tobacco smoke, strong fumes and fragrances, extremes of temperature and humidity) and pharmacotherapy based on the severity of asthma. The management of occupational rhinitis, which may accompany OA, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7945?source=see_link\">",
"     \"Occupational rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293008873\">",
"    <span class=\"h2\">",
"     Exposure avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure avoidance is the cornerstone of management of immunologic OA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. For comparison, the role of exposure avoidance in other forms of work-related asthma is also discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111252\">",
"    <span class=\"h3\">",
"     Immunologic occupational asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important intervention after identification of immunologic OA is prompt removal of the worker from further exposure to the sensitizing agent. Patients with OA generally have progressive deterioration in lung function if they remain in the working environment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], and fatal cases have occurred among workers with ongoing workplace exposure to either high-molecular-weight or low-molecular weight provocative antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/10\">",
"     10",
"    </a>",
"    ]. A description of high and low-molecular weight agents is provided separately (",
"    <a class=\"graphic graphic_table graphicRef66185 \" href=\"UTD.htm?27/53/28508\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link&amp;anchor=H1191269#H1191269\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\", section on 'Causative agents'",
"    </a>",
"    .) As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 156 subjects with OA (87 percent due to low-molecular-weight agents), forced expiratory volume in one second (FEV1) declined 101",
"      <span class=\"nowrap\">",
"       mL/year",
"      </span>",
"      during the last year of continued exposure (a clinically significant rate) and by 27",
"      <span class=\"nowrap\">",
"       mL/year",
"      </span>",
"      in the first few years following complete cessation of exposure (comparable to the rate among healthy adults) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Of 25 spray painters with OA due to toluene-diisocyanate (TDI) who were removed from exposure and retested approximately five years later, seven had continued sensitivity to TDI and continued active asthma, while eighteen had remission of asthma and TDI hyperresponsiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/12\">",
"       12",
"      </a>",
"      ]. Among these patients, a shorter duration of exposure after development of symptoms correlated with a greater the likelihood that asthma would remit, suggesting that early identification of OA and prompt cessation of exposure are key to a favorable outcome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link&amp;anchor=H1191269#H1191269\">",
"       \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\", section on 'Causative agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Workers with OA are likely to be sensitive to nonoccupational asthma triggers due to their increased bronchial hyperresponsiveness. Thus, the management plan should also include avoidance of other asthma triggers (eg, environmental tobacco smoke, extremes of heat and cold) at and away from work. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111259\">",
"    <span class=\"h3\">",
"     Irritant-induced asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete exposure avoidance is the preferred option for irritant-induced asthma. However, based on expert opinion and limited evidence, workers with nonimmunologic, irritant-induced asthma may be able to continue to work if the risk of a high-level exposure to the inciting agent is reduced by use of appropriate engineering controls and respiratory protective devices [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/13\">",
"     13",
"    </a>",
"    ]. Due to the irritant nature of the inciting agent, low dose exposures are less likely to cause an increase in symptoms, compared with immunologic inciting agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=see_link&amp;anchor=H8#H8\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111266\">",
"    <span class=\"h3\">",
"     Work-exacerbated asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with work-exacerbated asthma, avoidance of both work and nonwork-related asthma triggers (eg, environmental tobacco smoke, extremes of heat and cold) is important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953617198\">",
"    <span class=\"h2\">",
"     Exposure reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a few settings, modification or reduction of the exposure has allowed workers with OA to remain in the workplace, although data in support of this practice are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/7,13-18\">",
"     7,13-18",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 83 platinum refinery and catalyst production workers with OA, all of the workers who continued to be exposed continued to have symptoms, but only 50 percent of those with a reduced level of exposure continued to have symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/15\">",
"       15",
"      </a>",
"      ]. Among those who were transferred to an area with lower exposure compared with those who worked outside the plant or had left the plant, no differences were noted in forced expiratory volume in one second. However, the small numbers may have reduced the power to identify a difference between these groups and the workers who had left the plant may have had more severe OA.",
"     </li>",
"     <li>",
"      In a long-term follow-up study of 36 healthcare workers with latex-induced OA, 16 workers who were no longer exposed to latex were compared with 20 who had ongoing, but reduced exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/16\">",
"       16",
"      </a>",
"      ]. After a mean of 56 months, there was no significant difference between the groups in asthma severity score, FEV1, and nonspecific bronchial reactivity. This observational study may be biased in that those who continued work with reduced exposure may have had less severe OA.",
"     </li>",
"     <li>",
"      Among six polyurethane foam workers with OA due to toluene-diisocyanate (TDI), remaining in the workplace with less than 5 percent of the permissible exposure limit was associated with persistent asthma symptoms, persistent nonspecific bronchial hyperresponsiveness, and a decline in forced expiratory volume in one second (FEV1) of 15 percent over five years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link&amp;anchor=H11#H11\">",
"       \"Occupational asthma: Clinical features and diagnosis\", section on 'Nonspecific bronchoprovocation testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some workers with OA, often those with milder symptoms, may choose not to leave their workplace due to concerns about a reduction of income with job reassignment or unemployment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/18\">",
"     18",
"    </a>",
"    ]. Ongoing surveillance is advised for workers with OA who have continued low level exposure to a known causative agent. Evidence of further deterioration in asthma control or lung function should lead to renewed recommendations for complete avoidance of exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111823\">",
"    <span class=\"h2\">",
"     Respiratory protection devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Engineering and work practice controls are generally regarded as the most effective methods to control exposures to airborne hazardous substances. However, as an alternative, several respiratory protection devices (RPDs) are available to help protect workers from noxious occupational inhalants. These devices include air-purifying masks that filter particulates (eg, dust or particulate respirators) or chemically remove vapors or gases (eg, masks with cartridges or canisters) and powered air purifying respirators (also known as personal powered respirators, or PPRs) that supply clean air. The particular device is chosen based on the characteristics of the causative agent. These devices require proper fitting, careful removal practices, and regular maintenance. Patients with impaired pulmonary function at baseline may not tolerate the extra work of breathing through these devices. Further work is needed to evaluate efficacy with long-term use in the workplace.",
"   </p>",
"   <p>",
"    Data in support of using RPDs to reduce exposure to an agent known to have caused OA is limited to a few small case series that found only partial protection when the RPD was used in workers with OA due to high-molecular-weight agents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of a dust respirator (such as an N95 mask) was examined in two workers with OA due to buckwheat or wheat flour, one with only a late phase reaction and one with both early and late onset of asthma symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/20\">",
"       20",
"      </a>",
"      ]. Both early and late reactions were suppressed when the dust respirator was worn during workplace exposure. Information about long-term efficacy of the mask was not provided.",
"     </li>",
"     <li>",
"      The efficacy of personal powered respirators (PPRs) was assessed in 26 farmers by measuring pulmonary function after work-related dust exposure in the laboratory with and without the PPR [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/21\">",
"       21",
"      </a>",
"      ]. The PPR blunted the increase in airway resistance following dust exposure, but did not entirely prevent it.",
"     </li>",
"     <li>",
"      Personal powered respirators (PPR) were evaluated in 24 agricultural workers with OA [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/22\">",
"       22",
"      </a>",
"      ]. Morning and evening peak expiratory flow rates and daily symptoms of the subjects were monitored for 3 months without and for 10 months with the PPR. Morning peak flow rate improved with the PPR and daily variation in the peak flow rate diminished, consistent with improved asthma control. Occupational rhinitis also improved with use of the PPR. In a separate study, eight patients with OA due to laboratory animal allergy wore a PPR (Racal Airstream) during workplace exposure for seven weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/23\">",
"       23",
"      </a>",
"      ]. Six of the eight patients had adequate protection based on peak flow readings and a symptom diary.",
"     </li>",
"     <li>",
"      A laminar flow helmet with a high efficiency air purifying (HEPA) system was tested in 10 subjects with latex-induced OA, during challenges that simulated work exposure to latex gloves [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/24\">",
"       24",
"      </a>",
"      ]. The helmet with HEPA filtration was effective in preventing the asthma symptoms and fall in FEV1 that occurred during challenges without the helmet. However, it is not known whether this type of protection would be adequate protection against exposure to other high-molecular-weight causative agents in a work environment.",
"     </li>",
"     <li>",
"      Positive pressure helmets can be used by workers with OA caused by low-molecular-weight agents, if the duration of exposure is short. However, these protective devices are cumbersome and not well tolerated for longer intervals such as a work shift.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study is needed to determine whether any form of respirator would adequately prevent inhalation of a causative agent, such that a worker with OA could continue working in the same workplace.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293008866\">",
"    <span class=\"h2\">",
"     Pharmacologic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic treatment of OA is essentially the same as for non-occupational asthma, although it cannot replace exposure prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The general goals of pharmacologic therapy for asthma and the treatment of reactive airways dysfunction syndrome and irritant-induced asthma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H15#H15\">",
"     \"An overview of asthma management\", section on 'Pharmacologic treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=see_link&amp;anchor=H8#H8\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111387\">",
"    <span class=\"h3\">",
"     Assessment of disease severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the first steps in the management of occupational asthma is determining the severity of respiratory impairment as this will guide the choice of pharmacologic intervention. The assessment of OA severity follows the same principles described by the \"The National Asthma Education and Prevention Program: Expert Panel Report 3, Guidelines for the Diagnosis and Management of Asthma -- Full Report 2007\" (also known as the NAEPP guidelines), and is based on the severity and frequency of asthma symptoms, the anticipated risk of future exacerbations, and the degree of impairment of pulmonary function tests such as the forced expiratory volume in one second (FEV1) and the ratio of the FEV1 to the forced vital capacity (FVC) (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H16#H16\">",
"     \"An overview of asthma management\", section on 'Categories of asthma severity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111442\">",
"    <span class=\"h3\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of pharmacologic therapy for OA follows a step-wise approach, as described in the NAEPP and the Global Initiative for Asthma (GINA) guidelines (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A brief summary of this approach is described here; a more detailed discussion is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H15#H15\">",
"     \"An overview of asthma management\", section on 'Pharmacologic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For all workers with OA, a short-acting beta agonist (SABA) is prescribed for use as needed for quick relief of symptoms. For workers with mild, intermittent OA, this is usually the only pharmacologic therapy needed, especially if the worker is removed from further exposure (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18154?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of intermittent and mild persistent asthma in adolescents and adults\", section on 'Medications for intermittent asthma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with mild, moderate, or severe persistent OA, regular use of an inhaled glucocorticoid is added to &ldquo;as-needed&rdquo; use of the inhaled SABA (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 2",
"    </a>",
"    ). The evidence for the efficacy of inhaled glucocorticoids in OA is extrapolated from the large body of evidence supporting their use in nonoccupational asthma, and also from a few studies of patients with OA. When initiated shortly after diagnosis (in addition to removal from exposure), inhaled glucocorticoids have been found to produce a small but significant improvement in symptoms, lung function, and quality of life among patients with OA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. In the largest study, which started within three months of cessation of exposure, 32 subjects with OA caused by high or low-molecular-weight compounds were randomly assigned to take inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    1000",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/27\">",
"     27",
"    </a>",
"    ]. After one year, significant improvements were noted symptoms, morning and evening peak expiratory flow rates, and quality of life in the treatment group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18154?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of intermittent and mild persistent asthma in adolescents and adults\", section on 'Medications for mild persistent asthma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\", section on 'Initiating controller therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial dose of the inhaled glucocorticoid depends on the frequency and severity of symptoms, and also the degree of asthma control achieved with a prior dose of inhaled glucocorticoid, if any (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 3",
"    </a>",
"    ). For those who do not achieve good asthma control with a moderate to high dose of inhaled glucocorticoid, an inhaled long-acting beta2- adrenergic (LABA) bronchodilator is added to the regimen, based on the NAEPP guidelines and clinical experience rather than data from subjects with OA (",
"    <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H22#H22\">",
"     \"An overview of asthma management\", section on 'Initiating therapy in previously untreated patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H27#H27\">",
"     \"An overview of asthma management\", section on 'Assessing control to adjust therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe, poorly controlled asthma, characterized by frequent daytime or nocturnal symptoms, recent deterioration (eg, increased need for SABA), or a forced expiratory volume in one second (FEV1) less than 60 percent of predicted, may need an initial, brief course of oral glucocorticoid therapy to bring their asthma under control, in addition to initiation of inhaled glucocorticoid therapy at a high dose (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of severe asthma in adolescents and adults\", section on 'Initiating controller therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of pharmacologic therapy for OA is unknown. We typically re-assess asthma control at 8 to 12 week intervals. When asthma control is achieved, we taper the controller medications based on perceived efficacy, presence of adverse effects, patient preference, and cost considerations. Guidelines for tapering of inhaled GCs have not been validated, but we usually decrease by 20 to 25 percent increments at one to three month intervals to a medium or low dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H839256\">",
"    <span class=\"h3\">",
"     Subcutaneous immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous immunotherapy (SCIT) is occasionally considered in workers with OA who are unable or unwilling to change their work environment and are sensitized to high-molecular-weight agents for which appropriate allergen extracts are available. However, supportive data is limited, particularly regarding ongoing high level exposure, such as that experienced in a workplace. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H2#H2\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Indications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H10#H10\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Allergic asthma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence supporting the use of SCIT for OA comes from a few small studies of SCIT with high-molecular-weight antigens. As examples, two randomized trials have tested SCIT among patients with cat or dog dander-induced asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In one trial, 28 subjects were assigned to cat allergen SCIT or control and noted a marked reduction in symptoms during subsequent cat exposure without any significant adverse reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/30\">",
"     30",
"    </a>",
"    ]. In the other trial, SCIT improved symptoms related to cat exposure but not to dog exposure. Subsequent studies have confirmed that dog SCIT requires a high maintenance dose to achieve benefit, so the absence of benefit to dog SCIT in this study may have been due to an insufficient dose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H12#H12\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Effective allergens'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H24#H24\">",
"     \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Impact of SCIT with ongoing allergen exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two randomized trials of SCIT administered for OA involved healthcare workers sensitized to natural rubber latex [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. After specific SCIT, a significant improvement was observed in tolerance to direct exposure (glove-use test), but not in other parameters of asthma control, such as symptom scores, use of medication, or bronchial reactivity. Systemic reactions occurred in 69 percent of patients and after 8 percent of the doses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/35\">",
"     35",
"    </a>",
"    ]. Other case series have supported the efficacy of SCIT with latex extract, but also found a high rate of systemic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/34,36,37\">",
"     34,36,37",
"    </a>",
"    ]. However, SCIT is no longer a consideration for latex OA, as workplace practices to reduce latex exposure have subsequently improved to the point that SCIT is not needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17656?source=see_link&amp;anchor=H2#H2\">",
"     \"Anaphylaxis induced by subcutaneous allergen immunotherapy\", section on 'Overview'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40070?source=see_link\">",
"     \"Latex allergy: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several factors limit the use of SCIT for OA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only a few commercial extracts are available for agents that cause OA (eg, cat and dog dander, dust mites, pollen).",
"     </li>",
"     <li>",
"      The causative allergen for a number of animals is derived from urine, and SCIT extracts are not manufactured against allergens derived from bodily fluids (eg, rat, mouse, monkey) due to the risk of transmitting infectious agents.",
"     </li>",
"     <li>",
"      Mixed sensitization to several allergens may also be a problem. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link&amp;anchor=H344157047#H344157047\">",
"       \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\", section on 'Combined exposures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SCIT to foods, such as wheat, fish, shellfish or nuts, is not currently advised (outside of research settings) due to lack of data regarding safety or efficacy. However, a few case reports and case series have supported the use of SCIT to wheat extracts for bakers with OA [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/13,38,39\">",
"       13,38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systemic reactions have required modification or discontinuation of SCIT among many workers with OA [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/35,40\">",
"       35,40",
"      </a>",
"      ], and the risk of systemic reactions may be greater among these patients due to their high level of allergen exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/34,41\">",
"       34,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCIT, using low-molecular-weight allergens, has not been tested due to concerns about toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCIT has no role in the management of OA caused by corrosive or irritative substances.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H839354\">",
"    <span class=\"h3\">",
"     Anti-IgE therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-IgE therapy is typically indicated for patients with moderate-to-severe persistent asthma, demonstrable sensitivity to a perennial aeroallergen, and incomplete symptom control despite high dose inhaled glucocorticoid and a long-acting beta agonist. However, it is considered experimental therapy for OA, pending additional research on efficacy and safety. When caring for a patient with poorly-controlled OA, the strong recommendation would be for complete avoidance of the causative agent, rather anti-IgE therapy. (See",
"    <a class=\"local\" href=\"#H111252\">",
"     'Immunologic occupational asthma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of anti-IgE therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    ) has been described in a few case reports of bakers and healthcare workers who had poorly controlled asthma despite guideline-based pharmacologic therapy and were unable to change their work environment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Prior to considering anti-IgE therapy for OA, it would be necessary to document that IgE is a substantial contributor to the pathophysiology of OA in that individual. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H15#H15\">",
"     \"An overview of asthma management\", section on 'Pharmacologic treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link\">",
"     \"Anti-IgE therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with OA who have left the workplace, the indications for anti-IgE therapy are the same as those for asthma not related to occupational exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=see_link&amp;anchor=H7764932#H7764932\">",
"     \"Anti-IgE therapy\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111509\">",
"    <span class=\"h1\">",
"     DISABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Workers with severe OA may be unable to work for several months or longer even after cessation of exposure to the culprit agent. The criteria for and evaluation of pulmonary disability in the United States are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22873?source=see_link\">",
"     \"Disability assessment and determination in the United States\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32391?source=see_link\">",
"     \"Evaluation of pulmonary disability\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293008297\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement of OA is typically gradual after cessation of exposure and reaches a plateau after approximately two years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/43\">",
"     43",
"    </a>",
"    ], although some studies suggest that further improvement may occur later at slower rates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Most patients show incomplete resolution of asthma, airway responsiveness, and inflammation, even many years following cessation of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/14\">",
"     14",
"    </a>",
"    ]. However, a shorter duration of exposure prior to removal from the workplace appears to correlate with a higher rate of resolution of sensitization and bronchial hyperresponsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Resolution of sensitization is more common than resolution of bronchial hyperresponsiveness, which persists for a median of 3 years in approximately 73 percent of subjects with OA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even if asthma control improves with complete avoidance of exposure to the sensitizing agent, approximately one-half of workers with OA have persistent problems with depression and anxiety that are more severe than patients with a similar severity of non-work-related asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293008304\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of the level of exposure to sensitizing occupational antigens can reduce the number of workers who become sensitized and is the most important method of prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/19,51\">",
"     19,51",
"    </a>",
"    ]. The efficacy of reducing exposure levels has been demonstrated for acid anhydrides, detergent enzymes, isocyanates, laboratory animals, and latex [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/52-57\">",
"     52-57",
"    </a>",
"    ]. As examples, a threshold for flour exposure of 0.2",
"    <span class=\"nowrap\">",
"     mcg/m3",
"    </span>",
"    has led to a reduction in the risk of sensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/58\">",
"     58",
"    </a>",
"    ], and the incidence of OA due to isocyanates has decreased in association with better workplace exposure practices [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of respiratory protective equipment (RPE) decreases worker exposure levels and reduces the incidence, but does not completely protect against development of OA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/19,61\">",
"     19,61",
"    </a>",
"    ]. As an example, among 66 new hires at a plant using hexahydrophthalic anhydride, the use of RPE was associated with a decrease in the rate of developing occupational respiratory disease, including OA, from 10 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure monitoring, combined with medical surveillance of exposed workers, enables early identification of sensitization and removal from exposure for those who develop OA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Continuous monitoring of ambient levels of several low-molecular-weight chemicals, including isocyanates and formaldehyde, is now available. In addition, immunochemical techniques have been developed for quantifying ambient levels of high-molecular-weight allergens. Unfortunately, the very low concentration of antigen required to provoke bronchospasm once sensitization has occurred is often below the limits of detection.",
"   </p>",
"   <p>",
"    Because of the low predictive value of atopy for the development of OA and because nearly 50 percent of young adults are atopic, atopic subjects should not be excluded from high-risk workplaces. However, atopic individuals who enter high-risk workplaces require regular follow-up examinations for early detection of sensitization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchial hyperresponsiveness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link&amp;anchor=H9#H9\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\", section on 'Atopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoking cessation should be advised for general health reasons and may also decrease the risk of antigenic sensitization in the workplace [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It may be possible in the future to screen chemicals for their potential to induce respiratory allergy prior to their introduction into industry because studies have shown that the capacity for a chemical to cause sensitization is related to its structure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14489/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293008677\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are diagnosed with occupational asthma (OA) induced by an immunologic agent, we recommend complete cessation of exposure to the sensitizing agent (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H293008290\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For workers with mild OA (mild symptoms and minimal physiologic impairment) who have a strong preference for remaining in the workplace, reducing exposure via engineering controls or respiratory protective devices may be effective, but evidence is conflicting and &ldquo;safe&rdquo; levels of exposure have not been established. Careful ongoing surveillance is advised to detect any further deterioration in lung function. (See",
"      <a class=\"local\" href=\"#H953617198\">",
"       'Exposure reduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H111823\">",
"       'Respiratory protection devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic treatment of OA follows the same guidelines as non-occupational asthma, but cannot replace exposure prevention. For workers with OA who meet criteria for long-term controller therapy, we recommend inhaled glucocorticoids as the primary choice (",
"      <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The dose is based on the severity of asthma (",
"      <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H111442\">",
"       'Approach to treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H15#H15\">",
"       \"An overview of asthma management\", section on 'Pharmacologic treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is insufficient evidence of benefit in the setting of ongoing workplace exposure to advise the use of either subcutaneous immunotherapy (SCIT) or anti-IgE therapy (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      ) for the majority of patients with OA. However, for workers in the animal care professions who have OA caused by sensitization to cat or dog allergens and unavoidable workplace exposure, we suggest SCIT with the appropriate extract (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H839256\">",
"       'Subcutaneous immunotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H839354\">",
"       'Anti-IgE therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H10#H10\">",
"       \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Allergic asthma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=see_link&amp;anchor=H24#H24\">",
"       \"Subcutaneous immunotherapy for allergic disease: Indications and efficacy\", section on 'Impact of SCIT with ongoing allergen exposure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Improvement of OA after cessation of exposure is typically gradual and reaches a plateau approximately two years after cessation of exposure. Most patients show incomplete resolution of asthma, airway responsiveness, and inflammation, even many years following cessation of exposure. (See",
"      <a class=\"local\" href=\"#H293008297\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For many occupational sensitizers, control of the level of exposure to the sensitizing agent reduces the number of workers who become sensitized and is the most important method of prevention. (See",
"      <a class=\"local\" href=\"#H293008304\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bernstein IL, Chan-Yeung M, Malo JL, Bernstein DI. Definition and Classification of Asthma in the Workplace. In: Asthma in the workplace, 3rd, Bernstein IL, Chan-Yeung M, Malo IL, Bernstein DI (Eds), Taylor and Francis, New York 2006. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/2\">",
"      Dykewicz MS. Occupational asthma: current concepts in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2009; 123:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/3\">",
"      Mapp CE, Boschetto P, Maestrelli P, Fabbri LM. Occupational asthma. Am J Respir Crit Care Med 2005; 172:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/4\">",
"      Fishwick D, Barber CM, Bradshaw LM, et al. Standards of care for occupational asthma: an update. Thorax 2012; 67:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/5\">",
"      Baur X, Sigsgaard T, Aasen TB, et al. Guidelines for the management of work-related asthma. Eur Respir J 2012; 39:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/6\">",
"      Kim M-H, Jung J-W, Kang H-R. The Usefulness of Job Relocation and Serum Eosinophil Cationic Protein in Baker's Asthma. Int Arch Allergy Immunol 2013; 161:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/7\">",
"      Cote J, Kennedy S, Chan-Yeung M. Outcome of patients with cedar asthma with continuous exposure. Am Rev Respir Dis 1990; 141:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/8\">",
"      Moscato G, Dellabianca A, Perfetti L, et al. Occupational asthma: a longitudinal study on the clinical and socioeconomic outcome after diagnosis. Chest 1999; 115:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/9\">",
"      Pisati G, Baruffini A, Zedda S. Toluene diisocyanate induced asthma: outcome according to persistence or cessation of exposure. Br J Ind Med 1993; 50:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/10\">",
"      Ortega HG, Kreiss K, Schill DP, Weissman DN. Fatal asthma from powdering shark cartilage and review of fatal occupational asthma literature. Am J Ind Med 2002; 42:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/11\">",
"      Anees W, Moore VC, Burge PS. FEV1 decline in occupational asthma. Thorax 2006; 61:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/12\">",
"      Pisati G, Baruffini A, Bernabeo F, et al. Rechallenging subjects with occupational asthma due to toluene diisocyanate (TDI), after long-term removal from exposure. Int Arch Occup Environ Health 2007; 80:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/13\">",
"      Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. Chest 2008; 134:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/14\">",
"      Maghni K, Lemi&egrave;re C, Ghezzo H, et al. Airway inflammation after cessation of exposure to agents causing occupational asthma. Am J Respir Crit Care Med 2004; 169:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/15\">",
"      Merget R, Schulte A, Gebler A, et al. Outcome of occupational asthma due to platinum salts after transferral to low-exposure areas. Int Arch Occup Environ Health 1999; 72:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/16\">",
"      Vandenplas O, Jamart J, Delwiche JP, et al. Occupational asthma caused by natural rubber latex: outcome according to cessation or reduction of exposure. J Allergy Clin Immunol 2002; 109:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/17\">",
"      Banks DE, Rando RJ, Barkman HW Jr. Persistence of toluene diisocyanate-induced asthma despite negligible workplace exposures. Chest 1990; 97:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/18\">",
"      de Groene GJ, Pal TM, Beach J, et al. Workplace interventions for treatment of occupational asthma. Cochrane Database Syst Rev 2011; :CD006308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/19\">",
"      Nicholson PJ, Cullinan P, Taylor AJ, et al. Evidence based guidelines for the prevention, identification, and management of occupational asthma. Occup Environ Med 2005; 62:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/20\">",
"      Obase Y, Shimoda T, Mitsuta K, et al. Two patients with occupational asthma who returned to work with dust respirators. Occup Environ Med 2000; 57:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/21\">",
"      M&uuml;ller-Wening D, Neuhauss M. Protective effect of respiratory devices in farmers with occupational asthma. Eur Respir J 1998; 12:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/22\">",
"      Taivainen AI, Tukiainen HO, Terho EO, Husman KR. Powered dust respirator helmets in the prevention of occupational asthma among farmers. Scand J Work Environ Health 1998; 24:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/23\">",
"      Slovak AJ, Orr RG, Teasdale EL. Efficacy of the helmet respirator in occupational asthma due to laboratory animal allergy (LAA). Am Ind Hyg Assoc J 1985; 46:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/24\">",
"      Laoprasert N, Swanson MC, Jones RT, et al. Inhalation challenge testing of latex-sensitive health care workers and the effectiveness of laminar flow HEPA-filtered helmets in reducing rhinoconjunctival and asthmatic reactions. J Allergy Clin Immunol 1998; 102:998.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Full text available online: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm  (Accessed on November 01, 2010).",
"    </li>",
"    <li>",
"     Global initiative for asthma. Full text available online at:  file://www.ginasthma.com. (Accessed on November 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/27\">",
"      Malo JL, Cartier A, C&ocirc;t&eacute; J, et al. Influence of inhaled steroids on recovery from occupational asthma after cessation of exposure: an 18-month double-blind crossover study. Am J Respir Crit Care Med 1996; 153:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/28\">",
"      Maestrelli P, De Marzo N, Saetta M, et al. Effects of inhaled beclomethasone on airway responsiveness in occupational asthma. Placebo-controlled study of subjects sensitized to toluene diisocyanate. Am Rev Respir Dis 1993; 148:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/29\">",
"      De Marzo N, Fabbri LM, Crescioli S, et al. Dose-dependent inhibitory effect of inhaled beclomethasone on late asthmatic reactions and increased responsiveness to methacholine induced by toluene diisocyanate in sensitised subjects. Pulm Pharmacol 1988; 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/30\">",
"      Varney VA, Edwards J, Tabbah K, et al. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/31\">",
"      Sundin B, Lilja G, Graff-Lonnevig V, et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986; 77:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/32\">",
"      Lent AM, Harbeck R, Strand M, et al. Immunologic response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol 2006; 118:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/33\">",
"      Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2007; 119:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/34\">",
"      Leynadier F, Herman D, Vervloet D, Andre C. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 2000; 106:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/35\">",
"      Sastre J, Fern&aacute;ndez-Nieto M, Rico P, et al. Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003; 111:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/36\">",
"      Pereira C, Rico P, Louren&ccedil;o M, et al. Specific immunotherapy for occupational latex allergy. Allergy 1999; 54:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/37\">",
"      Pereira C, Pedro E, Tavares B, et al. Specific immunotherapy for severe latex allergy. Eur Ann Allergy Clin Immunol 2003; 35:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/38\">",
"      Armentia A, Martin-Santos JM, Quintero A, et al. Bakers' asthma: prevalence and evaluation of immunotherapy with a wheat flour extract. Ann Allergy 1990; 65:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/39\">",
"      Armentia A, Arranz M, Martin JM, et al. Evaluation of immune complexes after immunotherapy with wheat flour in bakers' asthma. Ann Allergy 1992; 69:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/40\">",
"      Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004; 113:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/41\">",
"      P&eacute;rez Pimiento A, Bueso Fern&aacute;ndez A, Garc&iacute;a Loria J, et al. Effect of omalizumab treatment in a baker with occupational asthma. J Investig Allergol Clin Immunol 2008; 18:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/42\">",
"      Olivieri M, Biscardo CA, Turri S, Perbellini L. Omalizumab in persistent severe bakers' asthma. Allergy 2008; 63:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/43\">",
"      Malo JL, Cartier A, Ghezzo H, et al. Patterns of improvement in spirometry, bronchial hyperresponsiveness, and specific IgE antibody levels after cessation of exposure in occupational asthma caused by snow-crab processing. Am Rev Respir Dis 1988; 138:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/44\">",
"      Perfetti L, Cartier A, Ghezzo H, et al. Follow-up of occupational asthma after removal from or diminution of exposure to the responsible agent: relevance of the length of the interval from cessation of exposure. Chest 1998; 114:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/45\">",
"      Malo JL, Ghezzo H. Recovery of methacholine responsiveness after end of exposure in occupational asthma. Am J Respir Crit Care Med 2004; 169:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/46\">",
"      Gautrin D, Ghezzo H, Infante-Rivard C, et al. Long-term outcomes in a prospective cohort of apprentices exposed to high-molecular-weight agents. Am J Respir Crit Care Med 2008; 177:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/47\">",
"      Rachiotis G, Savani R, Brant A, et al. Outcome of occupational asthma after cessation of exposure: a systematic review. Thorax 2007; 62:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/48\">",
"      Miedinger D, Malo JL, Ghezzo H, et al. Factors influencing duration of exposure with symptoms and costs of occupational asthma. Eur Respir J 2010; 36:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/49\">",
"      Yacoub MR, Lavoie K, Lacoste G, et al. Assessment of impairment/disability due to occupational asthma through a multidimensional approach. Eur Respir J 2007; 29:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/50\">",
"      Malo JL, Boulet LP, Dewitte JD, et al. Quality of life of subjects with occupational asthma. J Allergy Clin Immunol 1993; 91:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/51\">",
"      Cullinan P, Tarlo S, Nemery B. The prevention of occupational asthma. Eur Respir J 2003; 22:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/52\">",
"      Liss GM, Bernstein D, Genesove L, et al. Assessment of risk factors for IgE-mediated sensitization to tetrachlorophthalic anhydride. J Allergy Clin Immunol 1993; 92:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/53\">",
"      Cathcart M, Nicholson P, Roberts D, et al. Enzyme exposure, smoking and lung function in employees in the detergent industry over 20 years. Medical Subcommittee of the UK Soap and Detergent Industry Association. Occup Med (Lond) 1997; 47:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/54\">",
"      Drexler H, Schaller KH, Nielsen J, et al. Efficacy of measures of hygiene in workers sensitised to acid anhydrides and the influence of selection bias on the results. Occup Environ Med 1999; 56:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/55\">",
"      Fisher R, Saunders WB, Murray SJ, Stave GM. Prevention of laboratory animal allergy. J Occup Environ Med 1998; 40:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/56\">",
"      Allmers H, Schmengler J, Skudlik C. Primary prevention of natural rubber latex allergy in the German health care system through education and intervention. J Allergy Clin Immunol 2002; 110:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/57\">",
"      Tarlo SM, Easty A, Eubanks K, et al. Outcomes of a natural rubber latex control program in an Ontario teaching hospital. J Allergy Clin Immunol 2001; 108:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/58\">",
"      Malo JL, Chan-Yeung M. Agents causing occupational asthma. J Allergy Clin Immunol 2009; 123:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/59\">",
"      McDonald JC, Keynes HL, Meredith SK. Reported incidence of occupational asthma in the United Kingdom, 1989-97. Occup Environ Med 2000; 57:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/60\">",
"      Tarlo SM, Liss GM, Yeung KS. Changes in rates and severity of compensation claims for asthma due to diisocyanates: a possible effect of medical surveillance measures. Occup Environ Med 2002; 59:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/61\">",
"      Petsonk EL, Wang ML, Lewis DM, et al. Asthma-like symptoms in wood product plant workers exposed to methylene diphenyl diisocyanate. Chest 2000; 118:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/62\">",
"      Grammer LC, Harris KE, Yarnold PR. Effect of respiratory protective devices on development of antibody and occupational asthma to an acid anhydride. Chest 2002; 121:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/63\">",
"      Fishwick D, Barber CM, Bradshaw LM, et al. Standards of care for occupational asthma. Thorax 2008; 63:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/64\">",
"      Tarlo SM, Liss GM. Prevention of occupational asthma. Curr Allergy Asthma Rep 2010; 10:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/65\">",
"      Wild DM, Redlich CA, Paltiel AD. Surveillance for isocyanate asthma: a model based cost effectiveness analysis. Occup Environ Med 2005; 62:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/66\">",
"      Graham C, Rosenkranz HS, Karol MH. Structure-activity model of chemicals that cause human respiratory sensitization. Regul Toxicol Pharmacol 1997; 26:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14489/abstract/67\">",
"      Jarvis J, Seed MJ, Elton R, et al. Relationship between chemical structure and the occupational asthma hazard of low molecular weight organic compounds. Occup Environ Med 2005; 62:243.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15718 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14489=[""].join("\n");
var outline_f14_9_14489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H293008677\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H603599688\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293008290\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293008873\">",
"      Exposure avoidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111252\">",
"      - Immunologic occupational asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111259\">",
"      - Irritant-induced asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111266\">",
"      - Work-exacerbated asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H953617198\">",
"      Exposure reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111823\">",
"      Respiratory protection devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H293008866\">",
"      Pharmacologic treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111387\">",
"      - Assessment of disease severity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111442\">",
"      - Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H839256\">",
"      - Subcutaneous immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H839354\">",
"      - Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111509\">",
"      DISABILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293008297\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293008304\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293008677\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/15718\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/15718|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/53/28508\" title=\"table 1\">",
"      Causes of occupational asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/48/33549\" title=\"table 2\">",
"      Initiating Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/35/15934\" title=\"table 3\">",
"      Inhaled GC doses for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/48/38668\" title=\"table 4\">",
"      Usual doses inhaled GC-LABA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17656?source=related_link\">",
"      Anaphylaxis induced by subcutaneous allergen immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22873?source=related_link\">",
"      Disability assessment and determination in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32391?source=related_link\">",
"      Evaluation of pulmonary disability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40070?source=related_link\">",
"      Latex allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=related_link\">",
"      Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38903?source=related_link\">",
"      Occupational asthma: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7945?source=related_link\">",
"      Occupational rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/28/8650?source=related_link\">",
"      Reactive airways dysfunction syndrome and irritant-induced asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39049?source=related_link\">",
"      Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18154?source=related_link\">",
"      Treatment of intermittent and mild persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=related_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_9_14490="Neonatal thrombocytopenia";
var content_f14_9_14490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neonatal thrombocytopenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14490/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14490/contributors\">",
"     Caraciolo J Fernandes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14490/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14490/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14490/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/9/14490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/9/14490/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/9/14490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although thrombocytopenia is relatively rare in the general newborn population, it occurs frequently in patients admitted to newborn intensive care units. The major mechanisms are either increased destruction or decreased production of platelets. Multiple causes may be involved in some cases.",
"   </p>",
"   <p>",
"    Thrombocytopenia in the newborn is reviewed here. Evaluation of a child with a bleeding disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, neonatal thrombocytopenia has been defined as a platelet count less than",
"    <span class=\"nowrap\">",
"     150,000/microL",
"    </span>",
"    based upon the definition used in adults, which corresponds to values at or below the 5th percentile. However, healthy preterm and term newborns have counts significantly below this level [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was best illustrated from a study from the Intermountain Healthcare group that reviewed the platelet counts of 34,146 neonates (gestational age from 22 to 42 weeks) from the first three days of life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/2\">",
"     2",
"    </a>",
"    ]. In neonates, the 5th percentile was lower than the standard adult value of",
"    <span class=\"nowrap\">",
"     150,000/microL",
"    </span>",
"    and decreased with decreasing gestational age. For example, the 5th percentile was",
"    <span class=\"nowrap\">",
"     104,200/microL",
"    </span>",
"    for infants below 32 weeks gestation and was",
"    <span class=\"nowrap\">",
"     123,100/microL",
"    </span>",
"    for late preterm (34 to 36 weeks gestation) and term infants (gestational age greater than 37 weeks). Platelet counts increased with advancing postnatal age.",
"   </p>",
"   <p>",
"    Severe reductions (platelet count",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent thrombocytopenia can result in bleeding. Severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent thrombocytopenia requires evaluation, even in an asymptomatic infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SEVERE THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe thrombocytopenia, defined as a platelet count less than",
"    <span class=\"nowrap\">",
"     50,000/microL,",
"    </span>",
"    is rare (&lt;1 percent) in the general newborn population, as illustrated by the following two prospective studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelet counts",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"      were detected in 19 of 15,932 umbilical cord blood samples (0.12 percent) from consecutive deliveries in Hamilton, Ontario [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Platelet counts",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"      were found in 11 of 4489 consecutive cord blood samples (0.24 percent) in term infants in Finland [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/5\">",
"       5",
"      </a>",
"      ]. Two percent of the samples had platelet counts",
"      <span class=\"nowrap\">",
"       &lt;150,000/microL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neonates admitted to the NICU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe thrombocytopenia is more common in infants admitted to the neonatal intensive care units with reported incidence between 2.4 and 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The risk of thrombocytopenia is highest in the most premature infants. This was illustrated in a retrospective study of 284 extremely low birth weight (ELBW) infants (birth weight &lt;1000 g) born between 2003 and 2004 and cared for in one of four NICUs in Utah [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/8\">",
"     8",
"    </a>",
"    ]. Platelet counts of",
"    <span class=\"nowrap\">",
"     &lt;150,000/microL,",
"    </span>",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL",
"    </span>",
"    were detected in 73, 56, and 28 percent of ELBW infants, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of thrombocytopenia can be classified into disorders of increased destruction, including consumption, or decreased production (",
"    <a class=\"graphic graphic_table graphicRef52668 \" href=\"UTD.htm?38/13/39131\">",
"     table 1",
"    </a>",
"    ). In one review article, a cause for thrombocytopenia appeared to be more commonly found with severe thrombocytopenia (platelet count",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL)",
"    </span>",
"    than with moderate thrombocytopenia (platelet count 50,000 to",
"    <span class=\"nowrap\">",
"     100,000/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the prospective study of infants admitted to a NICU noted above, a potential cause for thrombocytopenia was identified in the majority [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/9\">",
"       9",
"      </a>",
"      ]. Increased platelet destruction was the most common mechanism. In some conditions (eg, necrotizing enterocolitis), a combination of mechanisms may be involved.",
"     </li>",
"     <li>",
"      In contrast, in the previously mentioned retrospective study of 202 ELBW preterm infants with thrombocytopenia, a cause could not be identified in almost half of the cases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/8\">",
"       8",
"      </a>",
"      ]. Identified contributing factors included small for gestational age and maternal history of preeclampsia (38 percent), neonatal infection (24 percent), neonatal disseminated intravascular coagulation (20 percent), and necrotizing enterocolitis (5 percent). There were no cases of neonatal alloimmune thrombocytopenia, maternal autoimmune thrombocytopenia, or drug-associated thrombocytopenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INCREASED DESTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased platelet destruction is seen in a number of conditions. Immune thrombocytopenia is a common cause, especially in otherwise healthy newborns. This disorder occurs when maternal antibody crosses the placenta and destroys neonatal platelets. In the French prospective study cited above, the incidence of immune thrombocytopenia in the general population was estimated at 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/10\">",
"     10",
"    </a>",
"    ]. A systematic review of prospective studies on screening pregnant women for HPA-1a antigen suggests 2.1 percent of the general population is negative for the HPA-1a antigen with 9.7 percent of the at-risk women subsequently developing antibodies to HPA-1a [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neonatal alloimmune thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal alloimmune thrombocytopenia (NAIT) occurs when fetal platelets contain an antigen inherited from the father that the mother lacks. The mother forms IgG class antiplatelet antibodies against the \"foreign\" antigen; these cross the placenta and destroy fetal platelets, resulting in fetal and neonatal thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/12\">",
"     12",
"    </a>",
"    ]. Plasma levels of thrombopoietin in these patients are normal because the megakaryocytes and platelets that are produced bind to this growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast to Rh sensitization, NAIT often develops in the first pregnancy of an at-risk couple.",
"   </p>",
"   <p>",
"    NAIT can result in severe thrombocytopenia in the fetus because platelet antigens form early in gestation and maternal antibodies cross the placenta in early midtrimester. The most serious complication is intracranial hemorrhage, which occurs in approximately 10 to 20 percent of affected newborns; one-quarter to one-half of these occur in utero [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/14\">",
"     14",
"    </a>",
"    ]. The risk of severe thrombocytopenia and intracranial hemorrhage is greater in alloimmune than in autoimmune thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Autoimmune thrombocytopenia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The extent and severity of NAIT was documented in 107 fetuses identified because of an affected older sibling [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/14\">",
"     14",
"    </a>",
"    ]. The initial platelet count obtained by fetal blood sampling (mostly between 20 and 32 weeks gestation) was",
"    <span class=\"nowrap\">",
"     &le;20,000/microL",
"    </span>",
"    in 50 percent, including 46 percent of the 46 fetuses studied before 24 weeks gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Platelet antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet antigens are designated as human platelet antigens (HPA) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/16\">",
"     16",
"    </a>",
"    ]. The different forms are designated by the suffix \"a\" (the more common allele) or \"b\" (the rarer allele) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 98 percent of Caucasians express the HPA-1a antigen (formerly known as PLA-1) on their platelets, whereas only 2.9 percent are homozygous for HPA-1b [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, the HPA-1 antigen is responsible for NAIT in approximately 75 to 90 percent of cases in Caucasians. In Asians, HPA-4",
"    <span class=\"nowrap\">",
"     (Yuk/Pen)",
"    </span>",
"    antigen is the most frequent cause of NAIT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Other antigens are involved less frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1,16,19-23\">",
"     1,16,19-23",
"    </a>",
"    ]. In one series of 200 confirmed cases of NAIT from Great Britain, the most commonly detected antibodies were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anti-HPA-1a &mdash; 75 percent",
"     </li>",
"     <li>",
"      Anti-HPA-5b &mdash; 16 percent",
"     </li>",
"     <li>",
"      Anti-HPA-15b &mdash; 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11709139\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of NAIT has been estimated at 1 in 1000 to 5000 births [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. A study from Great Britain reported a lower incidence of 12.4 cases per 100,000 births based on identification of cases from three independent sources of infants born between 2006 and 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mother of a newborn with NAIT is asymptomatic, although she or a sister may have a history of previously affected pregnancies. Affected newborns typically are otherwise healthy, with signs consistent with thrombocytopenia that is moderately severe to severe, including petechiae, bruising, and bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the previously mentioned case series of 123 live births with NAIT, clinical presentations included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin bleeding only &mdash; 47 percent",
"     </li>",
"     <li>",
"      No bleeding &mdash; 34 percent",
"     </li>",
"     <li>",
"      Intracerebral hemorrhage &mdash; 14 percent",
"     </li>",
"     <li>",
"      Other major organ bleeding (GI, lung, retina) &mdash; 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet counts often are less than",
"    <span class=\"nowrap\">",
"     10,000/microL.",
"    </span>",
"    The platelet count typically falls in the first few days after birth, then rises over the next one to four weeks as the antibody level declines [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the first affected child, antigen testing of mother's and father's platelets should be performed, and the mother's serum tested for antiplatelet alloantibody [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/27\">",
"     27",
"    </a>",
"    ]. If available, DNA testing can be performed on the maternal and paternal blood to identify the platelet antigen genotypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Term infants who are not ill and have no other risk factors for hemorrhage (eg, traumatic delivery) are transfused if the platelet count is",
"    <span class=\"nowrap\">",
"     &lt;30,000/microL",
"    </span>",
"    or if there are signs of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. The threshold for transfusion is higher",
"    <span class=\"nowrap\">",
"     (&lt;50,000/microL)",
"    </span>",
"    in preterm infants or in term infants who are ill or have risk factors (eg, fetal or neonatal distress). The initial evaluation should include a cranial ultrasound examination to detect hemorrhage. If an intracranial hemorrhage is present, the higher threshold should be used for platelet transfusion.",
"   </p>",
"   <p>",
"    Adequate platelet counts should be maintained during the first 72 to 96 hours because the risk of intracranial hemorrhage is highest during this period. After the infant has reached 96 hours of age, the decision to transfuse platelets depends upon clinical circumstances. (See",
"    <a class=\"local\" href=\"#H46\">",
"     'Indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Washed maternal platelets are preferred because they will not react with the maternally derived anti-platelet antibodies. The platelets should be irradiated to avoid graft-versus-host disease. Alternatively, donor platelets that are typed and matched in order to exclude the offending platelet antigen can be used. However the use of maternal platelets may delay the transfusions process as it make take up to 12 to 24 hours to collect and properly process the cells. In addition, it is highly unlikely that matched platelets will be available in an emergent setting.",
"   </p>",
"   <p>",
"    As a result, in an infant with severe thrombocytopenia or hemorrhage, random donor platelets should be used initially, although survival of incompatible platelets is short [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/29\">",
"     29",
"    </a>",
"    ]. In the meantime, arrangements can be made to acquire maternal platelets. Other possibilities include administration of \"universal\" platelet concentrates that are",
"    <span class=\"nowrap\">",
"     HPA-1a-negative/HPA-5b-negative",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/24\">",
"     24",
"    </a>",
"    ], or identify HPA-1a-negative women during pregnancy and performing elective Cesarean delivery with HPA-1a-negative platelets available for immediate transfusion, if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/32\">",
"     32",
"    </a>",
"    ]. However, these are expensive interventions and are not generally available.",
"   </p>",
"   <p>",
"    Treatment with high-dose intravenous gamma-globulin (IVIG) (400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three to four days or 1",
"    <span class=\"nowrap\">",
"     gm/kg",
"    </span>",
"    per day for one to three days) often is effective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. However, this approach takes longer than does a platelet transfusion to achieve a safe platelet count and thus should be used as adjunctive therapy. Because of the high rate of intracranial hemorrhage, a cranial ultrasound examination should be performed before hospital discharge in any affected infant with a platelet count",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17175?source=see_link\">",
"     \"Intravenous immune globulin in hematologic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours for one to three days) has been used by some as an adjunctive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/36\">",
"     36",
"    </a>",
"    ], however, studies on its efficacy are lacking. We currently do",
"    <strong>",
"     not",
"    </strong>",
"    use steroids as routine therapy for NAIT, but would consider it in instances where life-threatening thrombocytopenia persists despite platelet transfusions and IVIG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prenatal management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In families with an affected",
"    <span class=\"nowrap\">",
"     fetus/infant,",
"    </span>",
"    the rate of recurrence is more than 75 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/37\">",
"     37",
"    </a>",
"    ], and thrombocytopenia in the second affected child is always as or more severe than in the previous infant [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/38\">",
"     38",
"    </a>",
"    ]. Management options include fetal therapy with in-utero platelet transfusions either weekly or immediately before delivery or maternal therapy with intravenous immunoglobulins (IVIG), corticosteroids, or a combination of the two [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/12\">",
"     12",
"    </a>",
"    ]. Maternal immunoglobulin treatment does not appear to be associated with lymphocyte activation or premature maturation of the neonatal immune system [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/60/12232?source=see_link\">",
"     \"Prenatal management of neonatal alloimmune thrombocytopenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Autoimmune thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune thrombocytopenia is mediated by maternal antibodies that react with both maternal and infant platelets. This occurs in maternal autoimmune disorders, including immune thrombocytopenia (ITP) and systemic lupus erythematosus. The diagnosis usually is apparent from the mother's medical history and maternal thrombocytopenia. However, the platelet count of affected mothers may be normal after a splenectomy or if there is sufficient compensatory thrombopoiesis. Mothers of infants with unexplained neonatal thrombocytopenia should be investigated for the presence of an autoimmune disorder because neonatal thrombocytopenia can be the presenting sign [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link&amp;anchor=H8#H8\">",
"     \"Thrombocytopenia in pregnancy\", section on 'ITP during pregnancy and delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Healthy women without a history of an autoimmune disorder sometimes develop gestational thrombocytopenia that usually is mild [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/4,41\">",
"     4,41",
"    </a>",
"    ]. This condition may be a mild and transient form of ITP and is considered benign. Neonatal thrombocytopenia is rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link&amp;anchor=H3#H3\">",
"     \"Thrombocytopenia in pregnancy\", section on 'Gestational thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected infants typically are otherwise healthy. Clinical signs are consistent with thrombocytopenia, including petechiae, bruising, and bleeding. Ninety percent of infants born to mothers with ITP have safe",
"    <span class=\"nowrap\">",
"     (&gt;50,000/microL)",
"    </span>",
"    or normal platelet counts. Thrombocytopenia, when it occurs, is usually moderately severe, often in the range of 20,000 to",
"    <span class=\"nowrap\">",
"     50,000/microL,",
"    </span>",
"    although data vary widely [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/28\">",
"     28",
"    </a>",
"    ]. A summary of published case series of mothers with ITP suggests that there is a 10 and 4 percent risk that the newborn infant will have a platelet count of &lt;50,000 and",
"    <span class=\"nowrap\">",
"     &lt;20,000/microL,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk for thrombocytopenia in the infant appears to correlate with the severity of ITP in the mother. Neonatal thrombocytopenia may be predicted by the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mother has had a splenectomy",
"     </li>",
"     <li>",
"      The mother's platelet count has been less than",
"      <span class=\"nowrap\">",
"       50,000/microL",
"      </span>",
"      at some time during the pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An older sibling has had neonatal thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Platelet counts of infants born to mothers with ITP often decrease sharply during the several days after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The nadir typically occurs at two to five days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, infants need to be closely monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal management depends upon the severity of thrombocytopenia and the infant's clinical status and risk of bleeding. A platelet transfusion is given to infants with severe thrombocytopenia or clinical bleeding. However, transfusions may not be as effective as in NAIT because the autoantibodies usually will react with all donor platelets, including those of the mother. (See",
"    <a class=\"local\" href=\"#H46\">",
"     'Indications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Intravenous immune globulin (IVIG) should be administered. If thrombocytopenia is severe and persistent after IVIG therapy, some clinicians give a short course of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice a day by mouth for five days) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/35\">",
"     35",
"    </a>",
"    ], but the efficacy of this approach has not been proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Perinatal management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of ITP in early pregnancy includes the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    . IVIG can be used as a temporary treatment for severely affected women. IVIG may help delay splenectomy, the most effective treatment for severe disease, until after delivery.",
"   </p>",
"   <p>",
"    Several approaches have been proposed for the management of labor and delivery in women with ITP. Perinatal management of NAIT has evolved from an invasive to non-invasive approach which includes the use of antenatal IVIG, and appears to be both safe and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/45\">",
"     45",
"    </a>",
"    ]. Current recommendations are to manage the delivery in a conventional manner, without fetal platelet count determinations (eg, either percutaneous umbilical blood sampling or scalp vein sampling), and with cesarean delivery performed only for obstetrical indications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/33,45-47\">",
"     33,45-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link\">",
"     \"Thrombocytopenia in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Drug-related thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many drugs have been reported to cause thrombocytopenia. The usual mechanism is accelerated platelet destruction caused by drug-dependent antibodies. Drug-induced thrombocytopenia can also be caused by bone marrow suppression. This may occur following administration of chemotherapeutic agents to the mother or newborn infant for a malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"     \"Drug-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If maternal thrombocytopenia following drug exposure is mediated by IgG antibody, the antibody can cross the placenta and affect fetal platelets. Thus, the infant's platelet count should be monitored. Drugs that have been implicated include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4296?source=see_link\">",
"     quinidine",
"    </a>",
"    , penicillins,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/24/27017?source=see_link\">",
"     digoxin",
"    </a>",
"    , and antiepileptic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/46,48\">",
"     46,48",
"    </a>",
"    ]. Thrombocytopenia has been reported as a mild and transient complication of treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    , although data are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     Heparin",
"    </a>",
"    -induced thrombocytopenia is a rare side effect of heparin therapy in newborns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=see_link\">",
"     \"Management of thrombosis in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;If drug-associated thrombocytopenia is suspected, the offending agent should be withdrawn. Transfusions should be given for low platelet counts",
"    <span class=\"nowrap\">",
"     (&lt;20,000/microL)",
"    </span>",
"    or for bleeding. If an immune-mediated condition is suspected, IVIG can be used while awaiting confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PERIPHERAL CONSUMPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia may result from increased peripheral consumption of platelets.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hypersplenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia may be associated with an enlarged spleen. Underlying disorders resulting in splenomegaly include hemolytic anemia, congenital hepatitis, congenital viral infection, and portal vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/18,28\">",
"     18,28",
"    </a>",
"    ]. The clinical features depend upon the associated condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12840?source=see_link\">",
"     \"Approach to the child with an enlarged spleen\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management includes identification and treatment of the underlying cause. Platelet transfusions are given as needed. Splenectomy is considered if bleeding is uncontrollable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Kasabach-Merritt syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Kasabach-Merritt phenomenon was described first in 1940 as a syndrome of consumptive coagulopathy, now called disseminated intravascular coagulation, with capillary hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/51\">",
"     51",
"    </a>",
"    ]. This phenomenon is associated with kaposiform hemangioendotheliomas, an aggressive form of giant hemangioma, and not true common hemangiomas of infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Thrombocytopenia results from shortened platelet survival caused by sequestration of platelets in the vascular malformation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lesions are noted at birth in approximately 50 percent of patients. The male-to-female ratio approaches 1:1. Detection of visceral lesions requires imaging studies. Common locations, in order of frequency, include: trunk (including retroperitoneum), arms and shoulder, lower extremity, and cervicofacial. All patients have severe thrombocytopenia, hypofibrinogenemia, elevated fibrin degradation products, and fragmentation of red blood cells (eg, schistocytes, helmet cells).",
"   </p>",
"   <p>",
"    Management is directed at resolution of the hemangioma while supporting hemostasis by transfusion of blood products as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/55\">",
"     55",
"    </a>",
"    ]. Treatments include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day orally), interferon alfa, surgery, embolization, and chemotherapeutic agents, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/12/33993?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and actinomycin D [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Disseminated intravascular coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC) is a systemic process producing both thrombosis and hemorrhage. DIC is a complication of underlying illness, typically sepsis, asphyxia, meconium aspiration, or severe respiratory distress syndrome. The diagnosis is suggested by the associated illness, clinical presentation, moderate to severe thrombocytopenia, and the presence of microangiopathic changes on the peripheral blood smear. Confirming laboratory studies include prolonged prothrombin time, prolonged activated partial thromboplastin time, decreased plasma fibrinogen concentration, and increased fibrin degradation product or D-dimer levels.",
"   </p>",
"   <p>",
"    Treatment is directed at the underlying cause of DIC. Transfusions of platelets and fresh frozen plasma are given to maintain the platelet count",
"    <span class=\"nowrap\">",
"     &gt;50,000/microL",
"    </span>",
"    and the prothrombin time within the physiologic range. Fibrinogen concentration is maintained &gt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    with infusion of cryoprecipitate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia can result from infections caused by bacterial, viral, and fungal organisms. Mechanisms for thrombocytopenia induced by bacterial sepsis include DIC, endothelial damage, antibody-mediated, and platelet aggregation caused by adherence of bacterial products to platelet membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/57\">",
"     57",
"    </a>",
"    ]. Decreased platelet production due to injury to the megakaryocytes in bone marrow also may play a role.",
"   </p>",
"   <p>",
"    Thrombocytopenia may occur with viral infections, including congenital rubella and cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Mechanisms include platelet aggregation, loss of sialic acid from the platelet membrane caused by viral neuraminidase, and megakaryocyte degeneration resulting in decreased production [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/57\">",
"     57",
"    </a>",
"    ]. Splenomegaly and reticuloendothelial hyperactivity associated with most of these infections may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ]. Management consists of treating the underlying infection, and platelet transfusions if there is associated bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link&amp;anchor=H8#H8\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of TORCH infections\", section on 'Congenital cytomegalovirus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Necrotizing enterocolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing enterocolitis (NEC) is a syndrome of gastrointestinal necrosis that occurs in 2 to 10 percent of infants with birth weight less than 1500 g. Thrombocytopenia is a frequent finding and can result in significant bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/61\">",
"     61",
"    </a>",
"    ]. In the early stages of NEC, declining platelet counts correlate with the presence of necrotic bowel and worsening disease. The primary mechanism of thrombocytopenia appears to be platelet destruction, although this is not caused by DIC in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=see_link\">",
"     \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Levels of cytokines, including platelet activating factor (PAF), are increased in premature infants with NEC and correlate with the severity of the disease. Intestinal damage and inflammatory cell recruitment result from a cascade of cellular events that may be mediated at least in part by PAF. However, the role of PAF in causing thrombocytopenia associated with NEC is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=see_link\">",
"     \"Pathology and pathogenesis of necrotizing enterocolitis in newborns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia often accompanies thrombosis in newborns. Patients should be evaluated for a thromboembolic disorder if thrombocytopenia cannot be explained by other conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14600?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DECREASED PRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia caused by decreased platelet production often is associated with genetic disorders. Marrow infiltration due to neonatal leukemia, storage diseases, or neuroblastoma also can limit platelet production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Genetic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic disorders can result in isolated thrombocytopenia or thrombocytopenia associated with other clinical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Thrombocytopenia-absent radius syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia-absent radius (TAR) syndrome is an autosomal recessive disorder characterized by severe thrombocytopenia and bilateral absent radii, although the thumbs always are present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/62\">",
"     62",
"    </a>",
"    ]. Other abnormalities of the upper limbs may be present, including hypoplasia or absence of the ulna, or abnormal or absent humerus. Congenital heart disease, usually atrial septal defect or tetralogy of Fallot, occurs in approximately one-third of affected patients.",
"   </p>",
"   <p>",
"    Severe thrombocytopenia (platelet count &lt;10,000 to",
"    <span class=\"nowrap\">",
"     30,000/microL)",
"    </span>",
"    at birth or during the first postnatal week occurs in 59 percent of patients with TAR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ]. The thrombocytopenia is caused by dysmegakaryocytopoiesis, with differentiation blockade at the stage of an early megakaryocyte precursor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/63\">",
"     63",
"    </a>",
"    ]. The defect does not involve either thrombopoietin or the thrombopoietin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/14,63\">",
"     14,63",
"    </a>",
"    ]. The bone marrow shows normal erythroid and myeloid precursors with absent or decreased megakaryocytes.",
"   </p>",
"   <p>",
"    Mortality is significant in the neonatal period and early infancy, primarily due to intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/64\">",
"     64",
"    </a>",
"    ]. If the patient survives this period, spontaneous resolution of the thrombocytopenia usually occurs after the first year of age. Treatment is supportive with platelet transfusions given when needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Fanconi anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia caused by Fanconi anemia, an autosomal recessive disorder, is rare in the neonatal period. The mean age at diagnosis of the pancytopenia is approximately six to nine years. However, the condition may be recognized in the newborn by characteristic congenital malformations that are present in as many as 60 to 70 percent of affected patients. The most common malformations are hypopigmented spots, abnormality of thumbs, microcephaly, caf&eacute;-au-lait spots, and urogenital abnormalities; short stature of prenatal onset may be present (",
"    <a class=\"graphic graphic_table graphicRef71159 \" href=\"UTD.htm?14/12/14540\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link\">",
"     \"Inherited aplastic anemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Congenital amegakaryocytic thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital amegakaryocytic thrombocytopenia is a rare disorder that can result in severe neonatal thrombocytopenia (platelet count 0 to",
"    <span class=\"nowrap\">",
"     80,000/microL)",
"    </span>",
"    and near absence of megakaryocytes in the bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1,65,66\">",
"     1,65,66",
"    </a>",
"    ]. Pancytopenia develops in later childhood. The disorder is caused by mutations in the thrombopoietin receptor gene, c-mpl [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/65\">",
"     65",
"    </a>",
"    ]. The only effective treatment is allogeneic hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H18#H18\">",
"     \"Inherited aplastic anemia in children\", section on 'Amegakaryocytic thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Chromosome abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia may occur in infants with chromosome abnormalities, including trisomies 21, 18, and 13, and Turner syndrome, although the incidence in most of these conditions is not known. In one series of 25 newborns with trisomy 21, platelet counts",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL",
"    </span>",
"    occurred in 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chromosomal abnormalities contribute to a significant proportion of mild thrombocytopenia detected in utero. In a report of 247 cases of platelet counts",
"    <span class=\"nowrap\">",
"     &lt;150,000/microL",
"    </span>",
"    detected by consecutive fetal blood sampling, chromosome abnormality was the etiology in 43 (17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Congenital platelet disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some congenital platelet disorders are associated with thrombocytopenia. Examination of the peripheral smear often reveals the characteristic alterations in platelet morphology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=see_link&amp;anchor=H27#H27\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Abnormal platelet morphology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wiskott-Aldrich syndrome is a rare X-linked disorder that presents as a clinical triad of immunodeficiency, eczema, and moderate thrombocytopenia with small platelets. The mean platelet volume (MPV) in this condition is 3 to 5 fL; normal MPV is 7 to 10 fL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      May-Hegglin anomaly is an autosomal dominant trait characterized by giant platelets (MPV 30 to 80 fL), often with moderate thrombocytopenia, and leukocyte inclusion bodies.",
"     </li>",
"     <li>",
"      Bernard-Soulier syndrome is an autosomal recessive disorder of platelet function presenting with mild thrombocytopenia, circulating \"giant\" platelets, and bleeding.",
"     </li>",
"     <li>",
"      Alport syndrome (also called hereditary nephritis) is characterized by hematuria, progressive renal failure, and, in many families, deafness and ocular abnormalities. A few families have large platelets (MPV: 20 to 27 fL), thrombocytopenia, and leukocyte inclusions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"       \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Infiltrative disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow infiltrative disorders such as neonatal leukemia, neuroblastoma, or storage diseases can cause decreased platelet production. However, these are rare in the neonatal period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Toxic injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic injury to the megakaryocytes by infections or drugs can cause decreased platelet production. Thrombocytopenia usually is transient, and resolves when the offending agent is discontinued or the infection is treated successfully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia is associated with a variety of conditions that cannot be classified easily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Neonatal cold injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal cold injury following severe hypothermia may be manifested as refusal to eat, apathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    edema, and thrombocytopenia; the latter worsens during rewarming [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Massive pulmonary hemorrhage and other bleeding occur in patients who die while being rewarmed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/71\">",
"     71",
"    </a>",
"    ]. The mechanism may be increased sensitivity of rewarmed hypothermic platelets to ADP released from erythrocytes, resulting in irreversible platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Asphyxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Birth asphyxia is more common in newborns with than without thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/9,72,73\">",
"     9,72,73",
"    </a>",
"    ]. The mechanism is uncertain, but hypoxia may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Type 2B von Willebrand disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In type 2B von Willebrand disease (vWD), the structurally abnormal von Willebrand factor has increased affinity for its receptor (glycoprotein 1B) on the platelet [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. This may lead to platelet aggregation and thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H9#H9\">",
"     \"Classification and pathophysiology of von Willebrand disease\", section on 'Type 2B'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia, often associated with neutropenia, is common in infants of mothers with preeclampsia (formerly known as pregnancy-induced hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/77\">",
"     77",
"    </a>",
"    ]. The incidence of thrombocytopenia associated with this disorder has been estimated at 1 per 100 live births, and it is more likely to occur in preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In affected infants, thrombocytopenia typically is noted at birth or in the first few days after delivery. The nadir is reached at 2 to 4 days of age, with resolution by day 7 to 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The neutropenia seen in infants of women with preeclampsia is caused by decreased production mediated by an inhibitor of neutrophil production [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. It is likely that the associated thrombocytopenia is caused by a similar mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Dilution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia can occur after an exchange transfusion because the relatively large volume of platelet-poor transfused blood can dilute the concentration of circulating platelets. However, the condition for which the exchange transfusion was performed (eg, erythroblastosis fetalis) also can result in thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial approach to neonatal thrombocytopenia should take into account the infant's history and clinical condition. On the basis of this information, the etiology of the thrombocytopenia often can be recognized (",
"    <a class=\"graphic graphic_table graphicRef50212 \" href=\"UTD.htm?20/62/21485\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mother may have thrombocytopenia caused by a known condition, such as ITP or systemic lupus erythematosus, or a previous splenectomy. There may be a family history of bleeding disorders, or a previously affected infant. In the latter case, the fetal platelet count may be known from intrauterine sampling. A history of infection or drug exposure may be helpful.",
"   </p>",
"   <p>",
"    Details of the labor and delivery, the infant's condition at birth, and the need for resuscitation should be documented. Histopathologic examination of the placenta should be performed as it may provide clues to the diagnosis. The placenta may show evidence of congenital infection (eg, cytomegalovirus, syphilis), vasculopathy (eg, preeclampsia or other maternal vasculopathy), hemorrhage, infarcts, thrombi, and, rarely, vascular malformations or malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical condition should be assessed to determine if the infant is healthy or ill. Healthy infants are more likely to have immune or genetic causes of thrombocytopenia. Infants with systemic illness are more likely to have thrombocytopenia caused by infection, asphyxia, necrotizing enterocolitis, or DIC.",
"   </p>",
"   <p>",
"    The infant should be examined for evidence of bleeding, especially petechiae or large ecchymoses, cephalohematoma, or oozing from the umbilical cord or puncture sites. The presence of jaundice or hepatosplenomegaly might suggest congenital infection. Dysmorphic features, including skeletal abnormalities (eg, absent radii, limb hypertrophy), should be noted (",
"    <a class=\"graphic graphic_table graphicRef71159 \" href=\"UTD.htm?14/12/14540\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies will help establish the diagnosis. In an asymptomatic infant, thrombocytopenia may be detected because of maternal history or from a complete blood count (CBC) performed as part of an evaluation of an infant with risk factors for infection. A platelet count should be performed as part of a CBC in any infant with signs of bleeding or systemic illness. In either case, a low platelet count should be confirmed by repeat testing. The CBC should also be evaluated for anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neutropenia. Examination of the peripheral smear determines the platelet size, which can help distinguish between a destructive or consumptive process (large platelet size), and a decrease in platelet production (normal or small platelet size).",
"   </p>",
"   <p>",
"    Coagulation status should be evaluated with a prothrombin time (PT) and activated partial thromboplastin time (aPTT). Measurement of fibrinogen concentration and fibrin split products (d-dimer) should be performed in infants at risk for DIC.",
"   </p>",
"   <p>",
"    Infants who appear ill should be evaluated for sepsis. Depending upon the clinical presentation, evaluation for congenital infection or genetic testing may be indicated.",
"   </p>",
"   <p>",
"    The infant should be monitored for signs of bleeding. Urine, stool, and gastric aspirate (if the infant has a nasogastric tube) should be tested for blood.",
"   </p>",
"   <p>",
"    The mother's platelet count should be ascertained. If an immune cause of thrombocytopenia is considered and her platelet count is normal (in the absence of a splenectomy), platelet antigen typing of the mother and the newborn should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     PLATELET TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with thrombocytopenia that is severe or who have clinical bleeding require platelet transfusion. Guidelines are based upon clinical experience, as randomized controlled trials are difficult given the hemorrhage-related risks of not transfusing infants with severe thrombocytopenia. Few studies examining the impact of platelet transfusions upon neonatal outcome have failed to demonstrate either morbidity or mortality benefit following platelet transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/80-82\">",
"     80-82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise platelet level to transfuse newborns in order to prevent bleeding is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/83\">",
"     83",
"    </a>",
"    ]. In general, in a stable term infant, a platelet transfusion should be performed if the platelet count is",
"    <span class=\"nowrap\">",
"     &lt;20,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/84\">",
"     84",
"    </a>",
"    ]. In preterm infants or term infants who are unstable or have risk factors for hemorrhage, a transfusion should be administered if the platelet count is",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL.",
"    </span>",
"    Because the risk of intracranial hemorrhage is greatest in the immediate perinatal period, we maintain the platelet count by transfusion for at least the first 72 to 96 hours after birth. After 96 hours of age, the decision to transfuse platelets depends upon clinical circumstances in the individual patient.",
"   </p>",
"   <p>",
"    Clinical circumstances may modify these \"trigger\" guidelines. In our practice, higher levels are used in newborns who are receiving drugs that cause platelet dysfunction (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    , inhaled nitric oxide) or who are being treated with anticoagulants. Newborns with conditions such as DIC, in which platelets are consumed rapidly, also should be transfused at higher levels in anticipation of briskly falling platelet levels. In addition, platelet transfusion is performed in neonates prior to major surgery if the platelet count is",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets are obtained from a fresh unit of whole blood or by pheresis and prepared in a standard suspension. For infants who are premature (defined as a birth weight less than 1200 g), the preparation should be irradiated prior to use. In addition, leukocytes are removed during the pheresis process, thereby providing a cytomegalovirus-safe product. In general, administration of 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of platelet suspension will increase the platelet count from 50,000 to",
"    <span class=\"nowrap\">",
"     100,000/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H382870465#H382870465\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Ordering platelets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Volume reduction should not be done unless there is a need for strict volume restriction or recurrent severe allergic reaction. Volume reduction may be necessary when fluid restriction is critical, such as in patients with heart failure, oliguria or anuria due to renal injury, or generalized edema (eg, pleural effusion and ascites). Volume reduction may cause platelet activation due to centrifugation, resulting in a lower recovery of platelets. However, volume-reduced platelet transfusions appear to have similar efficacy to nonreduced preparations, as reported by a Dutch retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/85\">",
"     85",
"    </a>",
"    ]. In this study, neonates who received twice the dose of a volume-reduced platelet preparation compared with those receiving nonreduced products had double the platelet count within the first 24 hours after transfusion.",
"   </p>",
"   <p>",
"    In most cases, platelets from a random donor can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/29\">",
"     29",
"    </a>",
"    ]. In alloimmune thrombocytopenia, the donor must be antigen-compatible. If the condition is anticipated, the mother's platelets can be collected prior to delivery and used for transfusion. However, when ABO incompatible platelets need to be transfused, the plasma component should be reduced to avoid potential hemolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no established published guidelines for the administration of platelets in neonates. In our practice based on clinical experience, we routinely transfuse platelets via a peripheral intravenous catheters rapidly as the infant will tolerate the volume of infusion; this is usually over 30 minutes and no longer than two hours. Platelets should not be administered either through an arterial line or into the liver (ie, umbilical venous line) because of a high-risk of thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the outcome of severe neonatal thrombocytopenia and the effect of platelet transfusions. Two large observational studies have shown that most neonates with severe thrombocytopenia receive platelet transfusions according to previously recommended NICU thresholds (&lt;50,000 per microL). However, it remains unclear whether platelet transfusions were beneficial in the majority of infants with no or minor bleeding symptoms.",
"   </p>",
"   <p>",
"    In the first study of 3652 neonates, 5 percent developed severe neonatal thrombocytopenia defined as a platelet count less than 60,000 microL, with 34, 39, and 28 percent of infants having platelet counts nadirs of &lt;20,000; 20,000 to 39,000; and &gt;40,000 microL, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/6\">",
"     6",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among study infants, minor hemorrhage was noted in 73 percent, no bleeding in 18 percent, and major hemorrhage in 9 percent. There was no difference in the median platelet count among the three groups.",
"     </li>",
"     <li>",
"      Of the 15 major bleeding episodes, nine were due to intraventricular hemorrhage including one case of concomitant hematuria, three to pulmonary hemorrhage, and one case each of isolated hematuria, rectal bleeding, and intraabdominal bleeding. No relationship between platelet count and bleeding was demonstrated; however, gestational age &lt;28 weeks and postnatal age within 14 days of birth were associated with major hemorrhage. For severe IVH, the most common major hemorrhagic event, the majority (31 of 35) occurred before enrollment in the study.",
"     </li>",
"     <li>",
"      Platelet transfusions (n = 415) were administered to 116 infants (69 percent), primarily based upon a low platelet count. Platelet transfusions increased the median platelet counts from 27,000 to 79,000 microL. Mortality rates were highest for infants receiving five or more transfusions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the second study of 11,281 neonatal intensive care admissions, severe thrombocytopenia (defined as a platelet count less than 50,000 microL) was identified in 2.5 percent of neonates with 326 episodes of severe thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/9/14490/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous bleeding was most common in patients with platelet counts less than 20,000 microL. In contrast, there was no significant correlation between platelet count and pulmonary, gastrointestinal or intraventricular bleeding.",
"     </li>",
"     <li>",
"      Platelet transfusions were administered to 86 percent of patients.",
"     </li>",
"     <li>",
"      Mortality rate did not correlate with the lowest platelet count but increased with the number of platelet transfusions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25396378\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although thrombocytopenia is relatively rare in the general newborn population, it occurs frequently in patients admitted to newborn intensive care units.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although neonatal thrombocytopenia is defined as a platelet count less than",
"      <span class=\"nowrap\">",
"       150,000/microL,",
"      </span>",
"      only severe thrombocytopenia defined as a platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"      usually results in bleeding and requires evaluation and, potentially treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Severe thrombocytopenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of thrombocytopenia can be classified into disorders of increased destruction, including consumption, or decreased production (",
"      <a class=\"graphic graphic_table graphicRef52668 \" href=\"UTD.htm?38/13/39131\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of increased platelet destruction in neonates include neonatal alloimmune thrombocytopenia, autoimmune thrombocytopenia, and drug-related destruction of platelets. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Increased destruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of peripheral consumption of platelets in neonates include hypersplenism, Kasabach-Merritt syndrome, disseminated intravascular coagulation, infection, necrotizing enterocolitis, and thrombosis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Peripheral consumption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of decreased platelet production in neonates include genetic disorders (eg, thrombocytopenia-absent radius syndrome, Fanconi anemia, congenital amegakaryocytic thrombocytopenia, and congenital platelet disorders), bone marrow infiltrative diseases (eg, neonatal leukemia, neuroblastoma or storage diseases), and toxic megakaryocytes injury. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Decreased production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Miscellaneous causes that cannot be classified based on pathogenesis include neonatal cold injury, asphyxia, type 2B von Willebrand disease, and preeclampsia. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Miscellaneous causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial diagnostic approach to neonatal thrombocytopenia is based on evaluating the maternal and neonatal history including labor and delivery, and the infant&rsquo;s clinical condition. On the basis of this information, the etiology of the thrombocytopenia often can be recognized (",
"      <a class=\"graphic graphic_table graphicRef50212 \" href=\"UTD.htm?20/62/21485\">",
"       table 3",
"      </a>",
"      ). Laboratory studies that help establish the diagnosis include the complete blood count (including examination of the peripheral smear), coagulation studies, and reviewing the mother&rsquo;s platelet count.",
"     </li>",
"     <li>",
"      Patients with thrombocytopenia that is severe or who have clinical bleeding require platelet transfusion. Guidelines are based upon clinical experience because randomized controlled trials are difficult to conduct given the hemorrhage-related risks of not transfusing infants with severe thrombocytopenia.",
"     </li>",
"     <li>",
"      In our practice, we generally transfuse platelets for the following conditions. (See",
"      <a class=\"local\" href=\"#H46\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the term stable infant, when the platelet count is",
"      <span class=\"nowrap\">",
"       &lt;20,000/microL.",
"      </span>",
"     </li>",
"     <li>",
"      In preterm infants or clinically unstable term infants, when the platelet count is",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL.",
"      </span>",
"     </li>",
"     <li>",
"      Higher target levels may be indicated in neonates who receive drugs that cause platelet dysfunction such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"       indomethacin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      , or who have disseminated intravascular coagulation.",
"     </li>",
"     <li>",
"      Prior to major surgery, if the platelet count is",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/1\">",
"      Sola MC, Del Vecchio A, Rimsza LM. Evaluation and treatment of thrombocytopenia in the neonatal intensive care unit. Clin Perinatol 2000; 27:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/2\">",
"      Wiedmeier SE, Henry E, Sola-Visner MC, Christensen RD. Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system. J Perinatol 2009; 29:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/3\">",
"      Andrew M, Kelton J. Neonatal thrombocytopenia. Clin Perinatol 1984; 11:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/4\">",
"      Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med 1993; 329:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/5\">",
"      Sainio S, J&auml;rvenp&auml;&auml; AL, Renlund M, et al. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol 2000; 95:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/6\">",
"      Stanworth SJ, Clarke P, Watts T, et al. Prospective, observational study of outcomes in neonates with severe thrombocytopenia. Pediatrics 2009; 124:e826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/7\">",
"      Baer VL, Lambert DK, Henry E, Christensen RD. Severe Thrombocytopenia in the NICU. Pediatrics 2009; 124:e1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/8\">",
"      Christensen RD, Henry E, Wiedmeier SE, et al. Thrombocytopenia among extremely low birth weight neonates: data from a multihospital healthcare system. J Perinatol 2006; 26:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/9\">",
"      Castle V, Andrew M, Kelton J, et al. Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986; 108:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/10\">",
"      Dreyfus M, Kaplan C, Verdy E, et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood 1997; 89:4402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/11\">",
"      Kamphuis MM, Paridaans N, Porcelijn L, et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG 2010; 117:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/12\">",
"      Murphy MF, Bussel JB. Advances in the management of alloimmune thrombocytopenia. Br J Haematol 2007; 136:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/13\">",
"      Porcelijn L, Folman CC, de Haas M, et al. Fetal and neonatal thrombopoietin levels in alloimmune thrombocytopenia. Pediatr Res 2002; 52:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/14\">",
"      Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med 1997; 337:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/15\">",
"      Bussel JB, Zacharoulis S, Kramer K, et al. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 2005; 45:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/16\">",
"      Kaplan C. Immune thrombocytopenia in the foetus and the newborn: diagnosis and therapy. Transfus Clin Biol 2001; 8:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/17\">",
"      Homans A. Thrombocytopenia in the neonate. Pediatr Clin North Am 1996; 43:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/18\">",
"      George D, Bussel JB. Neonatal thrombocytopenia. Semin Thromb Hemost 1995; 21:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/19\">",
"      Davoren A, Curtis BR, Aster RH, McFarland JG. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 2004; 44:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/20\">",
"      Curtis BR, Ali S, Glazier AM, et al. Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion 2002; 42:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/21\">",
"      Rousseau J, Goldman M, David M. HPA-5b (Bra) neonatal alloimmune thrombocytopenia in Quebec: incidence and clinical outcome in 31 cases. Transfusion 2004; 44:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/22\">",
"      Castro V, Kroll H, Origa AF, et al. A prospective study on the prevalence and risk factors for neonatal thrombocytopenia and platelet alloimmunization among 9332 unselected Brazilian newborns. Transfusion 2007; 47:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/23\">",
"      Peterson JA, Gitter ML, Kanack A, et al. New low-frequency platelet glycoprotein polymorphisms associated with neonatal alloimmune thrombocytopenia. Transfusion 2010; 50:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/24\">",
"      Ghevaert C, Campbell K, Walton J, et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 2007; 47:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/25\">",
"      Knight M, Pierce M, Allen D, et al. The incidence and outcomes of fetomaternal alloimmune thrombocytopenia: a UK national study using three data sources. Br J Haematol 2011; 152:460.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson DB. Acquired platelet defects. In: Nathan and Oski's Hematology of Infancy and Childhood, Nathan DG, Orkin SH, Ginsberg D, Look AT (Eds), WB Saunders, Philadelphia 2003. p.1597.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/27\">",
"      Killie MK, Husebekk A, Kaplan C, et al. Maternal human platelet antigen-1a antibody level correlates with the platelet count in the newborns: a retrospective study. Transfusion 2007; 47:55.",
"     </a>",
"    </li>",
"    <li>",
"     Gorlin JB, Goorin AM. Hematologic problems: Thrombocytopenia. In: Manual of Neonatal Care, Cloherty JP, Stark AR (Eds), Lippincott-Raven, Philadelphia 1997. p.470.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/29\">",
"      Kiefel V, Bassler D, Kroll H, et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 2006; 107:3761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/30\">",
"      Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107:2639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/31\">",
"      Bassler D, Greinacher A, Okascharoen C, et al. A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia. Transfusion 2008; 48:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/32\">",
"      Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007; 110:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/33\">",
"      Letsky EA, Greaves M. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Maternal and Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis Task Force of the British Society for Haematology. Br J Haematol 1996; 95:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/34\">",
"      Ouwehand WH, Smith G, Ranasinghe E. Management of severe alloimmune thrombocytopenia in the newborn. Arch Dis Child Fetal Neonatal Ed 2000; 82:F173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/35\">",
"      Ovali F, Samanci N, Ermi�� B, et al. Alternative therapies for neonatal autoimmune thrombocytopenia. Vox Sang 1998; 74:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/36\">",
"      Bussel J. Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost 2009; 7 Suppl 1:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/37\">",
"      Kaplan C, Daffos F, Forestier F, et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood 1988; 72:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/38\">",
"      Herman JH, Jumbelic MI, Ancona RJ, Kickler TS. In utero cerebral hemorrhage in alloimmune thrombocytopenia. Am J Pediatr Hematol Oncol 1986; 8:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/39\">",
"      Radder CM, Roelen DL, van de Meer-Prins EM, et al. The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusions for fetal/neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2004; 191:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/40\">",
"      Tchernia G, Morel-Kopp MC, Yvart J, Kaplan C. Neonatal thrombocytopenia and hidden maternal autoimmunity. Br J Haematol 1993; 84:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/41\">",
"      Anteby E, Shalev O. Clinical relevance of gestational thrombocytopenia of &lt; 100,000/microliters. Am J Hematol 1994; 47:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/42\">",
"      Burrows RF, Kelton JG. Pregnancy in patients with idiopathic thrombocytopenic purpura: assessing the risks for the infant at delivery. Obstet Gynecol Surv 1993; 48:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/43\">",
"      Payne SD, Resnik R, Moore TR, et al. Maternal characteristics and risk of severe neonatal thrombocytopenia and intracranial hemorrhage in pregnancies complicated by autoimmune thrombocytopenia. Am J Obstet Gynecol 1997; 177:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/44\">",
"      Valat AS, Caulier MT, Devos P, et al. Relationships between severe neonatal thrombocytopenia and maternal characteristics in pregnancies associated with autoimmune thrombocytopenia. Br J Haematol 1998; 103:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/45\">",
"      van den Akker ES, Oepkes D, Lopriore E, et al. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG 2007; 114:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/46\">",
"      Nieminen U, Kekom&auml;ki R. Quinidine-induced thrombocytopenic purpura: clinical presentation in relation to drug-dependent and drug-independent platelet antibodies. Br J Haematol 1992; 80:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/47\">",
"      Greaves M, Letsky EA. Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. Br J Obstet Gynaecol 1997; 104:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/48\">",
"      Kelton JG, Meltzer D, Moore J, et al. Drug-induced thrombocytopenia is associated with increased binding of IgG to platelets both in vivo and in vitro. Blood 1981; 58:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/49\">",
"      Couser RJ, Ferrara TB, Wright GB, et al. Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room. J Pediatr 1996; 128:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/50\">",
"      Kumar RK, Yu VY. Prolonged low-dose indomethacin therapy for patent ductus arteriosus in very low birthweight infants. J Paediatr Child Health 1997; 33:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/51\">",
"      Kasabach HH, Merritt KK. Hemangioma with extensive purpura. Arch Dis Child 1940; 59:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/52\">",
"      Blei F. New clinical observations in hemangiomas. Semin Cutan Med Surg 1999; 18:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/53\">",
"      Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have \"true\" hemangiomas. J Pediatr 1997; 130:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/54\">",
"      Propp RP, Scharfman WB. Hemangioma-thrombocytopenia syndrome associated with microangiopathic hemolytic anemia. Blood 1966; 28:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/55\">",
"      Hall GW. Kasabach-Merritt syndrome: pathogenesis and management. Br J Haematol 2001; 112:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/56\">",
"      Blei F, Karp N, Rofsky N, et al. Successful multimodal therapy for kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon: case report and review of the literature. Pediatr Hematol Oncol 1998; 15:295.",
"     </a>",
"    </li>",
"    <li>",
"     Andrew M, Brooker LA. Hemostatic disorders in newborns. In: Avery's Diseases of the Newborn, Taeusch HW, Ballard RA (Eds), WB Saunders, Philadelphia 1998. p.1045.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/58\">",
"      Cooper LZ, Green RH, Krugman S, et al. Neonatal thrombocytopenic purpura and other manifestations of rubella contracted in utero. Am J Dis Child 1965; 110:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/59\">",
"      Oski FA, Naiman JL. Effect of live measles vaccine on the platelet count. N Engl J Med 1966; 275:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/60\">",
"      Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1997; 175:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/61\">",
"      Ververidis M, Kiely EM, Spitz L, et al. The clinical significance of thrombocytopenia in neonates with necrotizing enterocolitis. J Pediatr Surg 2001; 36:799.",
"     </a>",
"    </li>",
"    <li>",
"     Jones KL. Smith's recognizable patterns of human malformation, 6th ed, Elsevier Saunders, Philadelphia 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/63\">",
"      Letestu R, Vitrat N, Mass&eacute; A, et al. Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome. Blood 2000; 95:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/64\">",
"      Hedberg VA, Lipton JM. Thrombocytopenia with absent radii. A review of 100 cases. Am J Pediatr Hematol Oncol 1988; 10:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/65\">",
"      Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/66\">",
"      van den Oudenrijn S, Bruin M, Folman CC, et al. Three parameters, plasma thrombopoietin levels, plasma glycocalicin levels and megakaryocyte culture, distinguish between different causes of congenital thrombocytopenia. Br J Haematol 2002; 117:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/67\">",
"      Hord JD, Gay JC, Whitlock JA. Thrombocytopenia in neonates with trisomy 21. Arch Pediatr Adolesc Med 1995; 149:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/68\">",
"      Hohlfeld P, Forestier F, Kaplan C, et al. Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings. Blood 1994; 84:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/69\">",
"      Cohen IJ. Cold injury in early infancy. Isr J Med Sci 1977; 13:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/70\">",
"      Cohen IJ, Amir J, Gedaliah A, et al. Thrombocytopenia of neonatal cold injury. J Pediatr 1984; 104:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/71\">",
"      Cohen IJ. Room temperature ADP-induced first-stage hyperaggregation of human platelets: the cause of rewarming deaths by thrombocytopenia in neonatal cold injury. Pediatr Hematol Oncol 1991; 8:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/72\">",
"      Ropert JC, Dreyfus M, Dehan M, Tchernia G. [Severe neonatal thrombopenia. Analysis of the etiologic data on 64 cases]. Arch Fr Pediatr 1984; 41:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/73\">",
"      Oren H, Irken G, Oren B, et al. Assessment of clinical impact and predisposing factors for neonatal thrombocytopenia. Indian J Pediatr 1994; 61:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/74\">",
"      Grainick HR, Williams SB, McKeown LP, et al. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor. J Clin Invest 1985; 76:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/75\">",
"      Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980; 302:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/76\">",
"      Fressinaud E, Mazurier C, Meyer D. Molecular genetics of type 2 von Willebrand disease. Int J Hematol 2002; 75:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/77\">",
"      Murray NA, Roberts IA. Circulating megakaryocytes and their progenitors in early thrombocytopenia in preterm neonates. Pediatr Res 1996; 40:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/78\">",
"      Koenig JM, Christensen RD. Incidence, neutrophil kinetics, and natural history of neonatal neutropenia associated with maternal hypertension. N Engl J Med 1989; 321:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/79\">",
"      Koenig JM, Christensen RD. The mechanism responsible for diminished neutrophil production in neonates delivered of women with pregnancy-induced hypertension. Am J Obstet Gynecol 1991; 165:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/80\">",
"      Andrew M, Vegh P, Caco C, et al. A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. J Pediatr 1993; 123:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/81\">",
"      Kenton AB, Hegemier S, Smith EO, et al. Platelet transfusions in infants with necrotizing enterocolitis do not lower mortality but may increase morbidity. J Perinatol 2005; 25:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/82\">",
"      Bonifacio L, Petrova A, Nanjundaswamy S, Mehta R. Thrombocytopenia related neonatal outcome in preterms. Indian J Pediatr 2007; 74:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/83\">",
"      Murray NA, Howarth LJ, McCloy MP, et al. Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfus Med 2002; 12:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/84\">",
"      Calhoun DA, Christensen RD, Edstrom CS, et al. Consistent approaches to procedures and practices in neonatal hematology. Clin Perinatol 2000; 27:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/9/14490/abstract/85\">",
"      Honohan A, Van't Ende E, Hulzebos C, et al. Posttransfusion platelet increments after different platelet products in neonates: a retrospective cohort study. Transfusion 2013.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4979 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14490=[""].join("\n");
var outline_f14_9_14490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25396378\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SEVERE THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neonates admitted to the NICU",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INCREASED DESTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neonatal alloimmune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Platelet antigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11709139\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prenatal management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Autoimmune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Perinatal management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Drug-related thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PERIPHERAL CONSUMPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Kasabach-Merritt syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Necrotizing enterocolitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DECREASED PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Thrombocytopenia-absent radius syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Fanconi anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Congenital amegakaryocytic thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Chromosome abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Congenital platelet disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Infiltrative disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Toxic injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      MISCELLANEOUS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Neonatal cold injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Asphyxia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Type 2B von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Dilution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      PLATELET TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25396378\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4979\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4979|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/13/39131\" title=\"table 1\">",
"      Causes newborn thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14540\" title=\"table 2\">",
"      Malformations Fanconi anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/62/21485\" title=\"table 3\">",
"      Approach neo thrombocytopenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/34/12840?source=related_link\">",
"      Approach to the child with an enlarged spleen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=related_link\">",
"      Congenital rubella syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17175?source=related_link\">",
"      Intravenous immune globulin in hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=related_link\">",
"      Management of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14600?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28105?source=related_link\">",
"      Pathology and pathogenesis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/60/12232?source=related_link\">",
"      Prenatal management of neonatal alloimmune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=related_link\">",
"      Thrombocytopenia in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_9_14491="Survival in vasculitis";
var content_f14_9_14491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated five year survival rates of vasculitis syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vasculitis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent survival",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyarteritis nodosa",
"       </td>",
"       <td>",
"        60 to 80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Churg-Strauss syndrome",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity vasculitis",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Henoch-Sch&ouml;nlein purpura",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Giant cell arteritis",
"       </td>",
"       <td>",
"        98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Takayasu arteritis",
"       </td>",
"       <td>",
"        80 to 90",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated survival compared with normal population.",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14491=[""].join("\n");
var outline_f14_9_14491=null;
var title_f14_9_14492="Endoscopic Rx LGIB";
var content_f14_9_14492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Endoscopic therapy of lower intestinal bleeding",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Probe diameter&bull;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Coaptive pressure",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Electrogenerator settings*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Desired outcome",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Special features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Heater probe&bull;",
"       </td>",
"       <td class=\"subtitle2\">",
"        Bipolar probe&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiodysplasia",
"       </td>",
"       <td>",
"        Large&Delta;",
"       </td>",
"       <td>",
"        Light",
"       </td>",
"       <td>",
"        10-15 J",
"       </td>",
"       <td>",
"        10-15 W, 1 second pulses",
"       </td>",
"       <td>",
"        Bleeding stops/angiodysplasia obliterated",
"       </td>",
"       <td>",
"        Periphery of lesion treated before center; caution with right-sided lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diverticulosis",
"       </td>",
"       <td>",
"        Large&Delta;",
"       </td>",
"       <td>",
"        Light to moderate",
"       </td>",
"       <td>",
"        10-15 J",
"       </td>",
"       <td>",
"        15-20 W, 1-2 second pulses",
"       </td>",
"       <td>",
"        Bleeding stops/visible vessel flat",
"       </td>",
"       <td>",
"        Coaptive pressure may depend upon location (dome vs neck of diverticulum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postpolypectomy",
"       </td>",
"       <td>",
"        Large&Delta;",
"       </td>",
"       <td>",
"        Light to moderate",
"       </td>",
"       <td>",
"        10-20 J",
"       </td>",
"       <td>",
"        15-20 W, 1-2 second pulses",
"       </td>",
"       <td>",
"        Bleeding stops",
"       </td>",
"       <td>",
"        Snaring (tamponade) of polyp stalk without current may be adequate for early bleeds",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     J: Joules; W: Watts",
"     <br>",
"      * Preinjection with epinephrine solution can be considered before endoscopic coagulation.",
"      <br>",
"       &bull; Probe size, power settings, and coaptive pressure will necessarily vary depending on clinical experience and location of lesion. Repeated cautery to the same point increases risk of perforation.",
"       <br>",
"        &Delta; Large probe preferred if therapeutic endoscope used.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Zuckerman G, Prakash C. Gastrointest Endosc 1999; 49:231.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14492=[""].join("\n");
var outline_f14_9_14492=null;
var title_f14_9_14493="Medications associated with diarrhea";
var content_f14_9_14493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications associated with diarrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        System targeted by drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Cardiovascular",
"       </td>",
"       <td>",
"        Antiarrhythmics",
"       </td>",
"       <td>",
"        Digitalis",
"        <br/>",
"        Procainamide",
"        <br/>",
"        Quinidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihypertensives",
"       </td>",
"       <td>",
"        <p>",
"         ACE-inhibitors",
"         <br/>",
"         Angiotensin II receptor blockers*",
"         <br/>",
"         Beta-blockers",
"         <br/>",
"         Hydralazine",
"         <br/>",
"         Methyldopa",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholesterol-lowering agents",
"       </td>",
"       <td>",
"        Cholestyramine",
"        <br/>",
"        Clofibrate",
"        <br/>",
"        Gemfibrozil",
"        <br/>",
"        Statins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diuretics",
"       </td>",
"       <td>",
"        Acetazolamide",
"        <br/>",
"        Ethacrynic acid",
"        <br/>",
"        Furosemide",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Central nervous system",
"       </td>",
"       <td>",
"        Antianxiety drugs",
"       </td>",
"       <td>",
"        Alprazolam",
"        <br/>",
"        Meprobamate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiparkinsonian drugs",
"       </td>",
"       <td>",
"        Levodopa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other agents",
"       </td>",
"       <td>",
"        Anticholinergic agents",
"        <br/>",
"        Fluoxetine",
"        <br/>",
"        Lithium",
"        <br/>",
"        Tacrine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Endocrine",
"       </td>",
"       <td>",
"        Oral hypoglycemic agents",
"       </td>",
"       <td>",
"        Metformin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid replacement therapy",
"       </td>",
"       <td>",
"        Synthroid",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        Antiulcer/antacid drugs",
"       </td>",
"       <td>",
"        H2-receptor antagonists",
"        <br/>",
"        Magnesium containing antacids",
"        <br/>",
"        Misoprostol",
"        <br/>",
"        Proton pump inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bile acids",
"       </td>",
"       <td>",
"        Chenodeoxycholic acid",
"        <br/>",
"        Ursodeoxycholic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laxatives",
"       </td>",
"       <td>",
"        Cathartics",
"        <br/>",
"        Lactulose",
"        <br/>",
"        Sorbitol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatments for inflammatory bowel disease",
"       </td>",
"       <td>",
"        5-aminosalycilates (particularly olsalazine)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Musculoskeletal",
"       </td>",
"       <td>",
"        Gold salts",
"       </td>",
"       <td>",
"        Auranofin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsteroidal antiinflammatory drugs",
"       </td>",
"       <td>",
"        Ibuprofen",
"        <br/>",
"        Mefenamic acid",
"        <br/>",
"        Naproxen",
"        <br/>",
"        Phenylbutazone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatments for gout",
"       </td>",
"       <td>",
"        Colchicine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Other",
"       </td>",
"       <td>",
"        Antibiotics&bull;",
"       </td>",
"       <td>",
"        Amoxicillin",
"        <br/>",
"        Ampicillin",
"        <br/>",
"        Cephalosporins",
"        <br/>",
"        Clindamycin",
"        <br/>",
"        Neomycin",
"        <br/>",
"        Tetracycline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antineoplastic agents",
"       </td>",
"       <td>",
"        Many",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary",
"       </td>",
"       <td>",
"        Alcohol",
"        <br/>",
"        Sugar substitutes (eg, sorbitol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamins",
"       </td>",
"       <td>",
"        Magnesium",
"        <br/>",
"        Vitamin C",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACE: angiotensin converting enzyme.",
"     <br>",
"      * Olmesartan has been associated with sprue-like enteropathy.",
"      <br>",
"       &bull; Most antibiotics have been associated with diarrhea.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Holt PR. Diarrhea and malabsorption in the elderly. Gastroenterol Clin North Am 2001; 30:427.",
"       </li>",
"       <li>",
"        Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging 1998; 13:245.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14493=[""].join("\n");
var outline_f14_9_14493=null;
var title_f14_9_14494="Effect of exercise on pregnancy outcome";
var content_f14_9_14494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Studies examining the effects of exercise on pregnancy outcome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Author, year",
"      </td>",
"      <td class=\"subtitle1\">",
"       Study type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Activity type",
"      </td>",
"      <td class=\"subtitle1\">",
"       Activity period",
"      </td>",
"      <td class=\"subtitle1\">",
"       Size of study population",
"      </td>",
"      <td class=\"subtitle1\">",
"       Outcome",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        Effect of exercise on outcome",
"       </p>",
"       <p>",
"        Relative risks, odds ratios, and 95% CI",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Dempsey et al (2004)",
"      </td>",
"      <td rowspan=\"3\">",
"       Case-control",
"      </td>",
"      <td rowspan=\"3\">",
"       Recreational",
"      </td>",
"      <td>",
"       Year before pregnancy",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        155 cases",
"       </p>",
"       <p>",
"        386 control",
"       </p>",
"      </td>",
"      <td rowspan=\"10\">",
"       Gestational diabetes mellitus (GDM)",
"      </td>",
"      <td>",
"       <p>",
"        Any vs. none 0.45 (0.28-0.74)",
"       </p>",
"       <p>",
"        Vigorous vs. none 0.29 (0.16-.51)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       First 20 weeks of pregnancy",
"      </td>",
"      <td>",
"       <p>",
"        Any vs. none 0.52 (0.33-0.80)",
"       </p>",
"       <p>",
"        Vigorous vs. none 0.34 (0.19-0.63)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Both periods",
"      </td>",
"      <td>",
"       Active both vs. inactive both 0.40 (0.23-0.68)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Dempsey et al (2004)",
"      </td>",
"      <td rowspan=\"3\">",
"       Prospective",
"      </td>",
"      <td rowspan=\"3\">",
"       Recreational",
"      </td>",
"      <td>",
"       Year before pregnancy",
"      </td>",
"      <td rowspan=\"3\">",
"       909",
"      </td>",
"      <td>",
"       <p>",
"        Any vs. none 0.44 (0.21-0.91)",
"       </p>",
"       <p>",
"        &ge;4.2 hours/week vs. none 0.24 (0.10-0.64)",
"       </p>",
"       <p>",
"        &ge;21.1 MET-hours/week vs. none 0.26 (0.10-0.65)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Seven days before interview held at mean gestational age of 12.7 weeks",
"      </td>",
"      <td>",
"       <p>",
"        Any vs. none 0.69 (0.37-1.29)",
"       </p>",
"       <p>",
"        &ge;6.0 hours/week vs none 0.90 (0.45-1.80)",
"       </p>",
"       <p>",
"        &ge;28.0 MET-hours/week vs. none 0.67 (0.31-1.43)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Both periods",
"      </td>",
"      <td>",
"       Active both vs. inactive both 0.31 (0.12-0.79)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Zhang et al (2006)",
"      </td>",
"      <td>",
"       Prospective",
"      </td>",
"      <td>",
"       Recreational walking, stair-climbing",
"      </td>",
"      <td>",
"       Potentially 10 years before pregnancy",
"      </td>",
"      <td>",
"       21,765",
"      </td>",
"      <td>",
"       <p>",
"        Mean weekly total activity score highest vs. lowest quintile 0.81 (0.68-1.01)",
"       </p>",
"       <p>",
"        Mean weekly vigorous activity score highest vs. lowest quintile 0.77 (0.69-0.94)",
"       </p>",
"       <p>",
"        Brisk/very brisk walking vs. casual walking with no vigorous activity 0.66 (0.46-0.95)",
"       </p>",
"       <p>",
"        &ge;15 flights stairs/day vs &le;2 flights stairs/day with no vigorous activity 0.50 (0.27-0.90)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Oken et al (2006)",
"      </td>",
"      <td rowspan=\"2\">",
"       Prospective",
"      </td>",
"      <td rowspan=\"2\">",
"       Recreational",
"      </td>",
"      <td>",
"       Year before pregnancy 3 months before 26-28 weeks gestation",
"      </td>",
"      <td rowspan=\"2\">",
"       1805",
"      </td>",
"      <td>",
"       <p>",
"        Vigorous vs. none 0.56 (0.33-0.95)",
"       </p>",
"       <p>",
"        Vigorous vs. none 0.90 (0.47-1.70)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Both periods",
"      </td>",
"      <td>",
"       <p>",
"        Vigorous before and light/moderate or",
"       </p>",
"       <p>",
"        Vigorous during vs. light/moderate before and inactive during 0.49 (0.24-1.01)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dye et al (1997)",
"      </td>",
"      <td>",
"       Case-control",
"      </td>",
"      <td>",
"       Any exercise",
"      </td>",
"      <td>",
"       Entire pregnancy",
"      </td>",
"      <td>",
"       <p>",
"        372 cases",
"       </p>",
"       <p>",
"        12,404 controls",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        None vs. any 1.0 (0.8-1.3)",
"       </p>",
"       <p>",
"        BMI &gt;33.0 none vs. any 1.9 (1.2-3.1)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Sorensen et al (2003)",
"      </td>",
"      <td rowspan=\"3\">",
"       Case-control",
"      </td>",
"      <td rowspan=\"3\">",
"       Recreational",
"      </td>",
"      <td>",
"       Year before pregnancy",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        201 cases",
"       </p>",
"       <p>",
"        383 controls",
"       </p>",
"      </td>",
"      <td rowspan=\"5\">",
"       Preeclampsia",
"      </td>",
"      <td>",
"       <p>",
"        Any vs. none 0.67 (0.42-1.08)",
"       </p>",
"       <p>",
"        Vigorous vs. none 0.40 (0.23-0.69)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       First 20 weeks of pregnancy",
"      </td>",
"      <td>",
"       <p>",
"        Any vs. none 0.65 (0.43-0.99)",
"       </p>",
"       <p>",
"        Vigorous vs. none 0.46 (0.27-0.79)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Both periods",
"      </td>",
"      <td>",
"       Active both vs. inactive both 0.59 (0.35-0.98)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Saftlas et al (2004)",
"      </td>",
"      <td>",
"       <p>",
"        Nested",
"       </p>",
"       <p>",
"        Case-control",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Work activity",
"       </p>",
"       <p>",
"        Leisure time physical activity (LTPA)",
"       </p>",
"      </td>",
"      <td>",
"       Year before pregnancy &lt;16 weeks gestation",
"      </td>",
"      <td>",
"       <p>",
"        44 cases",
"       </p>",
"       <p>",
"        2422 controls",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Virtually none assessed",
"       </p>",
"       <p>",
"        Any LTPA vs. no LTPA 0.66 (0.35-1.22)",
"       </p>",
"       <p>",
"        Nonsedentary jobs vs. sedentary jobs 0.71 (0.37-1.36)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rudra et al (2005)",
"      </td>",
"      <td>",
"       Case-control",
"      </td>",
"      <td>",
"       Recreational",
"      </td>",
"      <td>",
"       Year before pregnancy",
"      </td>",
"      <td>",
"       <p>",
"        244 cases",
"       </p>",
"       <p>",
"        470 controls",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Perceived very strenuous to maximal exertion vs. perceived exertion of none to weak 0.22 (0.11-0.44)",
"       </p>",
"       <p>",
"        BMI &lt;25 trend of lower risk with increasing perception of exertion (P&lt;0.001)",
"       </p>",
"       <p>",
"        BMI &ge;25 trend of lower risk with increasing perception of exertion (P&lt;0.001)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Artal et al (2007)",
"      </td>",
"      <td>",
"       Intervention",
"      </td>",
"      <td>",
"       Moderate exercise program equivalent to 60 percent symptom-limited VO",
"       <sub>",
"        2max",
"       </sub>",
"      </td>",
"      <td>",
"       <p>",
"        Enrolled",
"       </p>",
"       <p>",
"        &lt;33 weeks gestation delivery",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Obese with GDM",
"       </p>",
"       <p>",
"        Exercise + diet (ED) n = 39",
"       </p>",
"       <p>",
"        Diet (D) n = 57",
"       </p>",
"      </td>",
"      <td>",
"       Weight-gain restriction",
"      </td>",
"      <td>",
"       <p>",
"        Percentage gaining weight during study",
"       </p>",
"       <p>",
"        ED vs. D (53.8 percent vs. 78.9 percent, P&lt;0.01)",
"       </p>",
"       <p>",
"        Mean weight gain/week ED vs. D (0.1 &plusmn; 0.4 kg vs. 0.3 &plusmn; 0.4 kg, P&lt;0.05)",
"       </p>",
"       <p>",
"        Percentage macrosomic infants born to women gaining weight during study (ED or D) vs. to women losing weight or having no mean weight change during study (17.9 percent vs. 4.2 percent, P = 0.12)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bung et al (1991)",
"      </td>",
"      <td>",
"       Randomized clinical trial",
"      </td>",
"      <td>",
"       Moderate exercise program equivalent to 50 percent VO",
"       <sub>",
"        2max",
"       </sub>",
"      </td>",
"      <td>",
"       <p>",
"        Enrolled",
"       </p>",
"       <p>",
"        &lt;33 weeks gestation to delivery",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Hispanic women with GDM",
"       </p>",
"       <p>",
"        Exercise + diet (EXE) n = 17",
"       </p>",
"       <p>",
"        Insulin + diet (INS) n = 17",
"       </p>",
"      </td>",
"      <td>",
"       Normalization of blood glucose",
"      </td>",
"      <td>",
"       Normalization of blood glucose achieved and maintained in EXE and INS groups within 1 week",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CI: confidence interval",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Gavard JA, Artal R. Effect of exercise on pregnancy outcome. Clin Obstet Gynecol 2008; 51:467. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14494=[""].join("\n");
var outline_f14_9_14494=null;
var title_f14_9_14495="Nodule of onchocerciasis";
var content_f14_9_14495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Onchocerciasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 243px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A painless subcutaneous nodule (arrow) inhabited by the adult filarilal worms of Onchocerca volvulus which is transmitted by the black fly. The female adult worms give rise to the microfilariae that produce the dermal and ocular manifestations of onchocerciasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of WA Krotoski. The Skin and Infection: A Color Atlas and Text, Sanders, CV, Nesbitt, LT Jr (Eds), Williams &amp;Wilkins, Baltimore 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_9_14495=[""].join("\n");
var outline_f14_9_14495=null;
